<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Helen R on Medium]]></title>
        <description><![CDATA[Stories by Helen R on Medium]]></description>
        <link>https://medium.com/@doctor_27995?source=rss-5cdabe6c0e18------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/1*GsKD1tHfRVFF96e53nXVgg.jpeg</url>
            <title>Stories by Helen R on Medium</title>
            <link>https://medium.com/@doctor_27995?source=rss-5cdabe6c0e18------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Thu, 19 Nov 2026 03:25:54 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@doctor_27995/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[ADHD Medication? Are we asking the wrong questions?]]></title>
            <link>https://medium.com/@doctor_27995/adhd-medication-are-we-asking-the-wrong-questions-b6e8b3e92c49?source=rss-5cdabe6c0e18------2</link>
            <guid isPermaLink="false">https://medium.com/p/b6e8b3e92c49</guid>
            <category><![CDATA[society]]></category>
            <category><![CDATA[adhd]]></category>
            <category><![CDATA[mental-health]]></category>
            <category><![CDATA[psychology]]></category>
            <category><![CDATA[life]]></category>
            <dc:creator><![CDATA[Helen R]]></dc:creator>
            <pubDate>Fri, 13 Nov 2026 18:54:11 GMT</pubDate>
            <atom:updated>2026-11-13T18:54:11.045Z</atom:updated>
            <content:encoded><![CDATA[<p><em>Planet ADHD, clinical pragmatism and the risk of NOT treating patients</em></p><p><strong>Scene 1</strong><br>Medicine is organised around doctors diagnosing, classifying and investigating disease, generally with multiple tests and a very paternalistic approach to gatekeeping medication, which is generally presented as potentially very dangerous or even morally bad. Terrifying side effects are promised unless the patient has been through a complex often multi stage ritual culminating in the doctor finally sanctioning a medication trial.</p><p><strong>Scene 2</strong><br>In times past, priests of many cultures made a very good living (and arguably still do) as custodians of mysterious and potentially dangerous divine powers, accessible only through sacred books, elaborate rites, rituals and offerings. Ordinary people were taught that only the priesthood possessed the knowledge and authority to mediate with these dangerous and unpredictable forces safely. Questioning the mythology, translating the sacred book, bypassing the rituals or attempting direct access was severely punished, maintaining the priesthood’s privilege and power.</p><p>See a parallel? How much of modern medicine’s elaborate system of diagnostic rituals, guarded prescriptions, terrifying drug warnings and professional sanctions is really so different? How about assuming patients are sensible (unless clearly not) around what matters most to patients, <strong>What will</strong> <strong>make me feel better?</strong></p><p><strong>Provocative, Moi??</strong><br>The analogy is deliberately provocative, but the question is serious: how much of this gatekeeping is genuinely necessary for patient safety, and how much reflects the historical organisation of medical authority?</p><p>Obviously folks I am not talking about really dangerous medications, cancer treatments etc. which really do need this approach, but after a 30 year career in psychiatry, latterly ADHD, I am increasingly convinced that much of medicine works backwards from the patients’ point of view.</p><p>We establish symptoms, order tests, await results, all to ensure that the patient fits into a box that we made, using research done in highly artificial conditions, as far from the real patient in front of us as can be. Often, the point of all this seems to be to deny patients access to medication unless they reach a threshold which we have set. Even if the treatment itself is safe and cheap.</p><p>Finally at the end of the ritual, assuming the patient has made the right obesiance and jumped through all the hoops, the lucky few get to try it. At which point we are back where we should have started. Did this treatment make this patient feel better?</p><p>And one outcome we never measure is the risk of not treating. The patient who never books the follow-up, never completes the investigation, never returns for the result or does all that and then falls below the threshold. They simply disappear from the pathway. Suffering, impaired functioning and lost opportunities caused by not treating are not recorded as adverse outcomes and don’t appear on the side effect labels. We rush to withhold treatment, but are remarkably incurious about the harms of NOT treating.</p><p>Has anyone else noticed the very odd professional culture around medication. Time and time again, treatment which are safe and low-risk for the vast majority are presented as highly dangerous and requiring elaborate diagnostic rituals and continuous professional control.</p><p>How about just letting the patient try safe treatments cautiously and report back, stopping it if it doesn’t suit them, continuing if they feel better. How about if we keep iterating use of this medication based on what our patients tell us, prescribing more if the response is good, moving it down the list if patients don’t respond well? How about if we evolve the explanation to actual patient feedback in real world situations? What could that look like?</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*_BL5LpfIwZWvcwo7K3WXIA.jpeg" /><figcaption>Gasp, it’s so beautiful…</figcaption></figure><p><strong>It looks like Planet ADHD</strong><br>Working remotely with patients who have executive functioning difficulties, who often struggle to access their GPs and often feel unseen and dismissed when they do, I need a safe and sensible way to keep the patient at the centre, with as few steps as possible and a constant feedback loop determining treatment approach. Closely supervised by me of course.</p><p><strong>Who benefits from restricting access? Not the patients<br></strong>Currently ADHD treatment as usually practised is terrible. Let’s start with the assessment, which in UK most patients have to pay for. It’s structured around gatekeeping access to the top 5% with the absolute most disabling level of symptoms.</p><p>I see no evidence that anyone has actually asked, what about the 5% below that? Would they not also benefit from safe, inexpensive and remarkably effective medication? I think yes.</p><p>It’s a bigger question than my little clinic can answer, but my suspicion is that we are condemning a lot of people to a lot of suffering.</p><p><strong>Societal disadvantage without ADHD treatment</strong><br>People with ADHD frequently struggle with linear language processing, yet our society is structured such that this mode of processing is rewarded above all other in education and work settings. Given the the incredible effectiveness of (cheap and safe) stimulant medication in dramatically improving that processing, why is it behind a wall? No seriously, why do we place such formidable barriers between people and treatment that might transform their functioning?</p><p><strong>Calm down dears<br></strong>Before everyone rushes to report me, I keep to the diagnostic gatekeeping and approved stimulant prescribing in my clinic because I want to keep practising, but my suspicion is that around 40% of patients with these difficulties could benefit from stimulant medication.</p><p>If I was in charge, I would remove the barriers which cause so much misery and so many stunted lives, and sell it in the pharmacy. Why not let the patients try it and keep taking if it helps. But that is too radical for today on Planet Earth. But once “sufficient” ADHD is proved by assessment , now we could bring in some much needed Planet ADHD awareness to optimise treatment to the patient.</p><p><strong>What happens after diagnosis?<br></strong>Shock, horror! Even after jumping through all these hoops, research shows that around half of ADHD patients stop their medication within a year. And generally not because it didn’t help. Let me be clear here. ADHD medication, done right, is life changing. While we are muttering about toxicity, dependence, tolerance and of course always, always blaming patients’ for poor choices, how about a bit of professional curiosity into why after all this effort and expense so many patients can’t continue with such an effective treatment?</p><p><strong>The blocks we put there<br></strong>Classifying stimulants as Schedule 2 controlled drugs, alongside diamorphine (heroin), without good evidence they cause the same harms, hardly helps. Nor does requiring the patient to send unnecessary repeated observations, and pay for annual reviews they often don’t need. And of course even after jumping every hoop, GPs can still refuse NHS prescribing. Too often patients with private diagnoses and good medication response are told they must join NHS assessment waiting lists that can extend for seven years.</p><p><strong>Not in my silo</strong><br>Medicine divides patients between specialties. The psychiatrist treats ADHD, the cardiologist investigates palpitations and PoTS, the endocrinologist considers metabolic abnormalities, the gastroenterologist looks at IBS and food intolerances; the rheumatologist looks at hypermobility, fibromyalgia and joint pain; asthma goes to the respiratory physician; the allergist looks at hay fever and other allergies; the dermatologist manages eczema, acne and rashes; the gynaecologist manages hormonal symptoms, and the immunologist may assess possible mast-cell disease. Each specialty has its own investigations which gatekeep access to often very simple treatments. Our poor patients spend years on waiting lists, accumulating borderline results and specialist opinions, often without receiving useful treatment. And of course this process builds the giant patient files which scream “heartsink” to future doctors.</p><p><strong>Can we stop blaming medication and patients for a minute?<br></strong>But what about the sympathetic overactivation that is often part of the ADHD phenotype? What about interoceptive muting, which leaves patients pushing through fatigue, unable to recognise problems until they can no longer sleep, get out of bed or function?</p><p>What about the Panorama programmes and newspaper articles? What about relentless medical misinformation which always, always blames patients poor choices or stimulant medication for every problem? The constant urging of patients and their doctors to abandon treatment rather than investigate what is actually happening? Have we considered the patterns (clear when you look for them) and asked whether we could improve on standard ADHD treatment, and allow patients to continue benefiting from life changing medication? Have we bollocks. Far easier to blame the patient, blame the stimulant, discontinue treatment and send the patient back to start. <strong>Where is our professional curiosity in the face of so much avoidable suffering?</strong></p><p><strong>Treatment not gatekeeping</strong><br>If you look at symptom groups, not box ticking, ADHD patients experience one interconnected set of difficulties which always sit along the same set of axes…..Planet ADHD is organised around that phenotype. We address interacting domains of dopamine regulation, metabolic function, hormonal influences, dysautonomia and physiological activation. Treatment is individualised according to the patient’s presentation and response.</p><p><strong>ADHD as a brain-body phenotype<br></strong>What happens when we stop blaming patients or medication and start looking for patterns? ADHD is conventionally understood as a disorder of attention, activity and impulse regulation. Yet if you ask, ADHD patients routinely present with a much broader constellation of difficulties: sensory dysregulation, disturbed sleep, autonomic symptoms, metabolic instability, hormonal sensitivity, fatigue, hypermobility and physiological overactivation. These are not unrelated comorbidities. Research increasingly identifies associations between ADHD and several of these features, suggesting overlapping physiological vulnerabilities that conventional diagnostic categories do not adequately capture.</p><p>For example, almost all my ADHD patients report chronic jaw clenching, even before medication but often worse on starting stimulant? How many emails do all ADHD clinics receive from newly diagnosed and treated patients, all saying “love the stimulant doc, but can’t sleep, getting palpitations or chewing my face off” (Lots). How many do we need before we think about it?</p><p>It turns out that simply taking a cheap magnesium supplement at night — improves sleep, reduces muscular tension and lets the patient continue their stimulant. Already we are better than every other clinic (that I know of, I really want to be wrong here) for noticing this and suggesting a cheap fix. But does the bar always have to be so low?</p><p><strong>Ladies please, can you not just wait 20 years?</strong><br>Let’s talk about female hormones. Recognition of the importance of hormone treatment for women’s health and happiness could transform so many lives, yet most of the women I see have never been offered hormonal intervention by their GPs. And stabilising hormonal burden often transforms the effectiveness of ADHD treatment.</p><p>And worse still. For women with ADHD, it is often the <em>rate of hormonal change</em>, rather than the absolute level, that appears to destabilise the system. Yet we are still using blood tests and arbitrary thresholds to gatekeep these cheap and incredible treatments.</p><p>So in my clinic, where we see symptoms, we work with the patients to try treatment. Micronised progesterone is not just a female hormone; its neuroactive metabolites influence GABAergic signalling, calm sympathetic overactivation and help sleep. Many women experience extraordinary benefits from the very first night. Of course while always safe, it is not perfect for everyone. What do we do? Well I tell them if it does not help or is poorly tolerated pause and email me. Simples. Cheap, accessible, potentially life-changing treatment, obstructed by a system which looks more interested in refusing treatment than clear clinical benefit.</p><p><strong>Welcome to Planet ADHD<br></strong>And this is Planet ADHD, start with straightforward, proportionate interventions, listen to the patient and keep iterating. Treatments that consistently produce striking benefits move up our priorities; those that help less move down or disappear. <strong>Every intervention must continually justify its place through patient benefit, and our theories begin, end and are constantly iterated by patient results.</strong></p><p>Turns out that the jaw tension, sleep disturbance and physiological overactivation are features of underlying sympathetic overactivation and are exacerbated, not created by treatment. As I tell my patients, it’s the price we pay for running on adrenaline. So let’s take it even without the stimulant. Brilliant. Why at night? Because sleep is central to everything, and because our exhausted patients won’t notice a subtle daytime benefit but will notice sleeping better. Proof of concept in a confusing information sphere.</p><p>For people with untreated ADHD, fatigue, pain, mental doom loops and sleep problems are too often constant, normalised parts of everyday life. We have to push through them to function at all. We tell ourselves and our doctors that we are fine. Until we are not. Then we panic.</p><p>By asking questions and seeing the patterns in the clinic, we see a clear ADHD brain-body phenotype. These days my new patients are given two parallel approaches. Optimise the stimulant, but also understand and optimise the underlying physiology. As patients improve, they become more able to recognise end points before collapse and burnout and learn to take care of themselves before that happens, rather than the usual ADHD style of pushing through everything until we can’t get out of bed, can’t sleep, can’t function.</p><p><strong>Infamy….infamy..</strong></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/843/1*WYbcBWAeHOib4x-C76ikRQ.jpeg" /><figcaption>“Infamy! Infamy! They’ve all got it in for me!</figcaption></figure><p>As so often, the late Kenneth Williams said it best. Even to think like this, we have to abandon medicine’s obsession with one-size-fits-all solutions. The suggestion that different groups of humans might have different physiological needs is still fraught with accusations of heresy. Medicine is only now, reluctantly, being dragged into acknowledging that that about half of humans are in fact women. But still there is far less research into women’s health and treatment needs than there is for men. People who are not white are behind women at the end of a very long queue.</p><p>Planet ADHD medications are cheap, effective and have been prescribed safely for decades. The problem is that physiological symptoms exist on sliding scales, while medicine has set up rigid binary thresholds to access treatment.</p><p>So I prescribe it. We cannot wait for the creaking juggernaut of medicine to catch up with what patients need now. How many more decades before the broader ADHD phenotype is recognised, researched and officially sanctioned, particularly when clinical trials routinely exclude the very patients with multiple coexisting conditions who populate our consulting rooms? <strong>My patients cannot afford to wait. In my clinic, we do it now.</strong></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=b6e8b3e92c49" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Scurvy…a deficiency of humility]]></title>
            <link>https://medium.com/@doctor_27995/scurvy-a-deficiency-of-humility-6d9e111d2775?source=rss-5cdabe6c0e18------2</link>
            <guid isPermaLink="false">https://medium.com/p/6d9e111d2775</guid>
            <category><![CDATA[psychology]]></category>
            <category><![CDATA[medicine]]></category>
            <category><![CDATA[history]]></category>
            <category><![CDATA[science]]></category>
            <category><![CDATA[society]]></category>
            <dc:creator><![CDATA[Helen R]]></dc:creator>
            <pubDate>Fri, 07 Aug 2026 17:35:38 GMT</pubDate>
            <atom:updated>2026-08-07T17:35:38.535Z</atom:updated>
            <content:encoded><![CDATA[<p>Why everyone needs more psychiatrists…….</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/512/1*bElFFvSYElSZNWCNWLXrdA.jpeg" /><figcaption>Good god man do you think treatment grows on trees…</figcaption></figure><p>Another day, another medical article that gets me thinking. I enjoy <a href="https://substack.com/@awaisaftab">Awais Aftab</a>’s writing, and his <a href="https://www.psychiatrymargins.com/p/how-the-citrus-cure-for-scurvy-was?hide_intro_popup=true">scurvy essay</a> is a superb story about how medicine can forget what once worked. But I’m not convinced by the implied policy moral: that when treatments disappoint at scale, the explanation is usually “degradation” rather than the more scientific possibility that the effect was never robust to begin with. The scurvy history, read carefully, seems to support the opposite conclusion: progress comes from identifying the active ingredient and engineering delivery that survives variation — not from insisting that only artisanal, high-status versions count as real treatment.</p><p>On the other hand, it is true that we are often told a reassuring story about medicine and progress: that knowledge accumulates, that error is gradually corrected, and that modern expertise sits securely on the shoulders of the past. The history of scurvy is unsettling precisely because it breaks that story.</p><p>Scurvy is a serious and potentially fatal disease caused by vitamin C deficiency. Gums become swollen and purple, teeth loosen, old wounds reopen, and limbs swell and blacken. Death eventually follows. Fresh fruits, vegetables, and even fresh meat contain vitamin C, and restoring it to the diet quickly cures the disease.</p><p>In 1747, British naval surgeon James Lind demonstrated that citrus fruit cured scurvy. By the 1790s, the Royal Navy had effectively eliminated scurvy by issuing lemon juice to sailors. This happened long before anyone knew what vitamin C was. The cure worked in practice, but was vulnerable without a correct theory.</p><p>Once the working explanation shifted from an unknown “antiscorbutic factor” to the belief that acidity was responsible, citrus prophylaxis became vulnerable to substitution and processing changes. Lemons were replaced by West Indian limes, which contain substantially less vitamin C, and juice was often heated, exposed to air, or stored in copper vessels. Copper ions accelerate oxidative degradation of vitamin C, so these practices could preserve an acidic “citrus” drink while progressively destroying the biologically relevant component.</p><p>At the same time, steam power shortened voyages and increased opportunities for resupply. As a result, fewer sailors spent long enough without fresh food to develop overt scurvy. Even weakened prophylaxis was often “good enough” under these altered conditions, so declining efficacy was masked by falling incidence. Direct clinical experience of scurvy prevention diminished, and institutional memory faded.</p><p>Scurvy was now only seen in environments where deprivation could again be prolonged: polar expeditions, prisons, workhouses, and other closed institutions. In these contexts, citrus prophylaxis was either absent or ineffective, diets were rigid, cost-constrained, and centrally controlled, and inmates had no agency to experiment or challenge medical framing. When members of Scott’s antarctic expedition got scurvy despite the inactivated lime juice, the theory was discarded.</p><p>The broader intellectual climate reinforced this shift. Late-19th-century medicine was dominated by the rapid success of germ theory and infectious disease models. In that context, it was natural for clinicians to reinterpret scurvy through toxin or putrefaction theories, including the idea that “ptomaines” arising from spoiled or preserved foods were causative. These explanations sounded modern, aligned with prevailing scientific advances, and seemed to account for some observations — particularly when citrus appeared unreliable and fresh meat (which does contain vitamin C) sometimes offered partial protection. The theories advanced confidently, but sadly for patients the advance was in the wrong direction.</p><p>In retrospect, the failure was not a lack of intelligence or diligence, but a failure to acknowledge uncertainty. A correct theory is not required to preserve an effective practice; an admission of ignorance would have sufficed. Had clinicians recognised that they did not know the active ingredient, they might have treated substitutions and processing with greater caution. Instead, a confident but incorrect theory permitted changes that degraded efficacy, while environmental change concealed the consequences. By the time scurvy reappeared in settings where the old empirical cure was unavailable, clinicians were forced to invent new explanations rather than rediscover what had once worked.</p><p>This very interesting story is used to convey the importance of professional humility….here meaning humility of everyone else towards doctors. Patients would be safe if only everyone would leave treatment to doctors and stop trying to substitute cheaper alternatives….So what can we learn?</p><h3>The missing vitamin</h3><p>I think Awais Aftab is right about the core lesson of the scurvy story. When evidence looks messy, contradictory, or illogical, it is often because we lack the right conceptual lens. Before the concept of a vitamin existed, the same observations could support multiple internally coherent but incompatible theories. Fresh meat preventing scurvy fit the ptomaine model just as easily as the deficiency model. Without the missing concept, it was not obvious which results were anomalous and which were signal.</p><p>Where I want to extend rather than reject this argument is in asking <em>what kind</em> of missing factor we should be looking for in psychiatry. The dominant assumption — often implicit — is that psychopathology reflects loss of function, broken mechanisms, or deficits to be repaired. Treatments are then interpreted as “fixing” what is wrong. When effects vary across people or degrade at scale, the temptation is to attribute this to dilution, poor delivery, or loss of therapeutic context.</p><p>But the scurvy analogy allows a different possibility: what if many of these conditions are not primarily failures of function, but <strong>markers of a different phenotype</strong>? Not a deficit model, but a variation model. In that framing, treatments do not restore normality so much as <em>interact with a particular biological–psychological architecture</em>, sometimes helpfully, sometimes not, depending on context.</p><p>This would explain several otherwise puzzling features of psychiatric evidence. Why the same medication can be life-changing for one person and intolerable for another. Why different SSRIs are not interchangeable at the individual level despite being treated as equivalent in guidelines. Why psychotherapies show modest average effects but intense individual variability. And why scaling does not merely “degrade” treatment, but selectively reveals that an intervention only fits certain phenotypic configurations.</p><p>On this reading, the analogy is not that psychotherapy or medication is like lime juice degraded by copper tubing. It is that psychiatry may be in a pre-vitamin stage with respect to <strong>phenotype</strong>. We are averaging across biologically and psychologically distinct groups and then mistaking the resulting noise for degradation. The intervention has not been neutralised; it has been applied to people for whom it was never biologically or cognitively appropriate.</p><p>This also reframes humility. The lesson of scurvy is not simply that we should speak more softly, but that we should be careful what kind of certainty we abandon. The dangerous certainty was not confidence in citrus, but confidence about <em>why</em> citrus worked. Likewise, the danger in psychiatry may lie less in treatment itself than in assuming that treatment response tells us directly about pathology. A therapy can be genuinely useful without revealing the nature of the underlying condition — just as fresh meat cured scurvy without telling doctors what vitamin C was.</p><p>In that sense, Aftab’s call for epistemic humility is exactly right. Where I would push further is to suggest that the missing concept may not be a hidden lesion or broken mechanism at all, but a <strong>recognition that many so-called disorders are expressions of human variation interacting badly with modern environments</strong>. Until we can see phenotype clearly, we will keep mistaking heterogeneity for confusion, and variation for degradation.</p><p>If the lesson of scurvy is that confusion often reflects a missing variable rather than therapeutic incoherence, then the question for psychiatry is not whether we are humble enough, but whether we are looking for the right kind of missing factor. I want to suggest that what is absent from most psychiatric theory is not a molecular lesion or a more refined symptom checklist, but <strong>phenotype</strong>: a recognisable, coherent human subtype with characteristic neurocognitive, physiological, emotional, and social properties.</p><p>In this phenotype, what we label as “psychopathology” is not primarily loss of function, but <em>mismatch</em>. The core bottleneck is language processing under load. Auditory, visual (reading), and expressive language all degrade sharply under stress, novelty, or emotional arousal. Executive dysfunction is not laziness or disorganisation, but a chronic adrenergic alarm state that hijacks sequencing, initiation, and working memory. Social anxiety is not fear of people as such, but the repeated experience of language failing in real time — small talk collapsing, hierarchy navigation becoming opaque, nuance missed, timing wrong — followed by burning shame.</p><p>The physiology is equally distinctive. Sensory sensitivity is high across modalities. Histamine signalling is often exaggerated, contributing to fatigue, “brain fog”, sleep disruption, and inflammatory reactivity. Connective tissue differences are common, bringing pain, proprioceptive noise, autonomic instability, and a body that never quite settles. Metabolic and hormonal differences are frequent: insulin resistance, weight volatility, energy crashes, cyclical worsening around hormonal shifts, and in women, dramatic sensitivity to the luteal phase. These are not incidental comorbidities; they are part of the same architecture.</p><p>Within this frame, many psychiatric diagnoses begin to look like <strong>surface descriptions of downstream states</strong>, not distinct diseases. Anxiety is emotional dysregulation driven by sustained sympathetic activation. Depression is not a primary mood disorder, but burnout: shutdown, collapse, and conservation after years of running a much steeper internal hamster wheel. “Social anxiety” is what happens when a language-processing phenotype is repeatedly punished in fast, hierarchical social environments. PTSD reflects a nervous system with limited buffering capacity combined with delayed processing and avoidance; trauma overwhelms, then cannot be integrated. Bipolar disorder often resolves into ADHD-driven mood instability once sleep, stimulation, and autonomic tone are stabilised. Psychosis, in this model, appears at the extreme end: autistic literalism, sensory overload, sleep deprivation, and unbuffered stress coalescing into rigid interpretations when meaning-making finally breaks.</p><p>Crucially, this phenotype also explains why standard psychiatric practice so often feels incoherent. Treatments appear inconsistent because we are averaging across at least two fundamentally different human architectures. One group tolerates standard doses, benefits modestly from generic interventions, and fits well with one-size-fits-all protocols. The other reacts strongly to everything: side effects at “normal” doses, paradoxical responses, dramatic sensitivity to timing, context, hormones, sleep, and environment. In this second group, scaling does not merely “degrade” treatment; it reveals that the treatment was never designed for them.</p><p>Once the phenotype is recognised, treatment stops looking mysterious. Stimulants work not because they “treat ADHD” in the abstract, but because they stabilise language processing and reduce adrenergic noise. Magnesium helps because it quiets neuromuscular and autonomic reactivity. Antihistamines help because histamine tone is part of the load. Fluids, electrolytes, and compression support autonomic stability. Metformin helps some not because they are “metabolically sick”, but because insulin resistance amplifies fatigue and cognitive volatility. In women, micronised progesterone can be transformative, not by “treating mood”, but by steadying a nervous system exquisitely sensitive to hormonal fluctuation. When these are combined — carefully, at lower doses, with attention to timing — the person does not merely feel “less ill”. They function as they always could have, had the environment been built for their physiology.</p><p>Seen from this angle, much of my earlier life in psychiatry now looks uncomfortably like a prolonged placebo experiment. Not because patients were imagining benefit, but because we were applying blunt tools to a heterogeneous population and then mistaking partial, context-dependent improvements for evidence of general mechanisms. Without phenotype, psychiatry is condemned to confusion: diagnoses that blur into one another, treatments that work “sometimes”, side effects dismissed as idiosyncrasy, and outcomes that resist prediction. With phenotype, the field suddenly acquires internal coherence.</p><p>This, I think, is fully compatible with Aftab’s call for humility. The missing factor may not be a finer-grained disorder, but a recognition that many psychiatric syndromes are <strong>expressions of a particular human variant interacting badly with modern demands</strong>. Until we are conceptually ready for phenotypic treatment, psychiatry will continue to look illogical. But the illogic is not in the patients, nor in the treatments — it is in the frame we are still using to understand them.</p><h3>Doctors are always right</h3><p>Err not exactly. First, it demonstrates that clinicians can be wrong — persistently, confidently, and collectively — for extremely long periods of time. Not because they lack intelligence or goodwill, but because plausible narratives harden into professional common sense. The ptomaine theory “worked” well enough to survive. It explained some observations, failed to explain others, and yet remained dominant because there was no conceptual framework for micronutrients. Evidence did not speak for itself. Doctors filled the gaps with story.</p><p>Second, it demonstrates that <em>apparent efficacy tells you nothing about causation</em>. Citrus “worked”, fresh meat sometimes worked, lime juice sometimes failed, and multiple theories could be made to fit the same patchy outcomes. In hindsight, we know why. At the time, certainty was unwarranted but abundant.</p><p>Third — and this is the part often glossed over — it demonstrates that the single most reliable reduction in scurvy did not come from doctors, but from engineering. Steam power shortened voyages. Exposure time fell below the threshold for deficiency. Scurvy declined regardless of theory. That was a real, population-level success achieved by changing constraints, not by perfecting a clinical ritual.</p><h3>And this matters why?</h3><p>This matters because the scurvy story is now being redeployed as a moral lesson about modern psychiatry, in particular advocating long term clinician delivered psychotherapy (the author’s favourite).</p><p>The scurvy analogy is being used to imply that if a treatment stops working when you try to make it cheaper, more accessible, or more standardised, the fault lies with delivery rather than with the treatment itself. This move is extraordinarily convenient.</p><h3><strong>Switcheroo</strong></h3><p>The argument runs roughly as follows: treatments may still work even if doctors’ explanations are wrong; but when outcomes disappoint, it is likely because great interventions have been “degraded” by scale, standardisation, cost-cutting, or institutional pressure; and therefore non doctors should be humble about dismissing high-intensity, relationship-heavy, expert-delivered care and especially humble if thinking about replacing expensive doctor delivered treatments with cheaper professionals (lime juice) or standardised versions (copper containers) which may destroy the treatment altogether.</p><h3>Heads I win tails you lose</h3><p>This protects favoured interventions from falsification by redefining failure as contamination. If outcomes are good, the treatment is validated. If outcomes are mediocre, the active ingredient was diluted. If outcomes are poor, the system corrupted it. If cheaper alternatives perform similarly, they are dismissed as “lime juice”. If they perform worse, the explanation is ready-made.</p><p>The author calls for humility, but who is being called to be humble and who is apparently too great to need it??</p><h3>Is this even science?</h3><p>Here’s the thing. Science is not defined by narrative plausibility, professional consensus, or moral seriousness. It is defined by falsifiability and reproducibility under variation.</p><p>Here is the crucial point: if an intervention only “works” under elite conditions — long duration, highly trained practitioners, high cost, low scalability — and reliably loses effect as soon as you modify it in any way, the most parsimonious conclusion is not that you have discovered a sacred but fragile truth. The parsimonious conclusion is that you have misunderstood either <em>whether it works at all</em> or <em>why it appears to work</em>. The scientific response to such a pattern should not be reverence, but a one way trip to the bin.</p><p>Psychotherapy is not exempt from this lesson. There is no robust evidence that psychotherapy, as a class of interventions, possesses a specific, reproducible mechanism that survives control for expectancy, therapist allegiance, selection effects, regression to the mean, and non-specific human factors such as attention, meaning-making, and social validation. What <em>is</em> robust is that people often improve over time, that distress fluctuates, and that a warm reliable contact of pretty much any kind helps. On this “evidence” we should be setting up petting zoos for patients, not paying psychiatrists salaries.</p><p>When advocates respond to this by saying “ah, but you degraded it,” they are not practising humility. They are performing a status-preserving manoeuvre. They are asserting, without evidential privilege, that the <em>real</em> treatment is the one delivered under conditions that only a professional elite can provide — and that any attempt to democratise, scale, or economise care is epistemically suspect.</p><p>The honest lesson of the scurvy story, properly understood, teaches the opposite lesson. Doctors were wrong for a very long time; their explanations were confident, elegant, non-falsifiable and mistaken; and real progress came first from from changing the environment so the problem no longer arose and much later from identifying the true active ingredient. Steam power did far more for sailors than medical theory.</p><p>To invoke that history in defence of interventions that fail under standardisation is therefore a category error. Professional self-confidence and lack of robustness are seen as depth, non-reproducibility is reframed as proof of subtlety and all so that we can elevate status-preserving practice above the discipline that science actually demands.</p><p>An article that presents this inversion as epistemic sophistication is not advancing scientific humility but using the language of science to protect a professional hierarchy from scientific scrutiny.</p><h3>Cui bono (sigh)</h3><p>If we take that lesson seriously, then any narrative that conveniently preserves professional privilege should immediately raise suspicion, especially if it is framed to be unfalsifiable. This is not cynicism; it is methodological hygiene. When an argument’s practical effect is to declare that only expensive, long-term, high-status interventions are “real,” and that failures elsewhere prove degradation rather than weakness, you should distrust it until proven otherwise. Not because it must be false, but because professional incentives to believe it are overwhelming.</p><p>True humility would cut both ways. It would apply scepticism not only to biological reductionism or protocolised care, but also to cherished therapeutic hierarchies and status bias. It would admit the possibility that what we think “works” may be largely non-specific, context-dependent, or misattributed. It would seriously entertain the idea that system design — sleep, work structure, autonomy, poverty reduction, access to effective medication, and technological constraint-shifting — may move outcomes more than guarding a professional fortress.</p><h3>Who’s humble now?</h3><p>The scurvy allegory is powerful, but not for the reason the essay implies. It does not vindicate the idea that only high-status treatments are real and that scaling is inherently corrupting. It demonstrates something colder: clinicians can be wrong for a very long time; narratives can remain compelling because they preserve identity; and real progress often comes from identifying the active ingredient and engineering stable, scalable delivery — or from structural changes that prevent the problem altogether.</p><p>If a story about humility is actually protecting professional privilege, the correct response is not reverence but scepticism. In that sense, the scurvy story becomes a mirror: it warns us less about lost cures, and more about noticing who is telling the story, whether they are in fact humble and whose privilege all this humility is designed to protect.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=6d9e111d2775" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Ἁμαρτία — Father’s Day 2026]]></title>
            <link>https://medium.com/@doctor_27995/%E1%BC%81%CE%BC%CE%B1%CF%81%CF%84%CE%AF%CE%B1-fathers-day-2026-b998a4414abd?source=rss-5cdabe6c0e18------2</link>
            <guid isPermaLink="false">https://medium.com/p/b998a4414abd</guid>
            <category><![CDATA[poetry]]></category>
            <category><![CDATA[family]]></category>
            <category><![CDATA[life]]></category>
            <dc:creator><![CDATA[Helen R]]></dc:creator>
            <pubDate>Tue, 07 Jul 2026 16:10:42 GMT</pubDate>
            <atom:updated>2026-07-07T16:10:42.742Z</atom:updated>
            <content:encoded><![CDATA[<p><em>In Greek drama, The tragic error, miscalculation, or personal flaw of the protagonist that initiates their downward trajectory</em></p><p>You were the golden god of my childhood,<br>I nursed on my mother’s bitter hatred<br>The bastard who rejected her<br>Apparently, I was just like you<br>Callous, rejecting, sloughing us off<br>The detritus of a first family.</p><p>When they met, she was golden too — <br>Aphrodite, oozing with sumptuous sex<br>He was fascinated, drawn to the fierce flame<br>Then got the hell out of there, badly singed.<br>So easy to marry a monster by mistake</p><p>He learned his lesson and never looked back<br>Except there was me<br>I went to the palace once a year<br>My mother’s rageful howls<br>made it a magic kingdom, a fairy realm<br>where I longed to belong.</p><p>One problem: I was unwanted, shameful<br>a stupid, clumsy klutz<br>I felt my father’s hatred, the burning shame<br>How could the golden god have sired this hideous wen?</p><p>It wasn’t a surprise that shortly after his real golden daughter was born<br>I was forced to take a blood test<br>I was 12, FFS. I knew they wanted to be rid of me<br>But no — unbelievably, it seemed that I was his child<br>We’ve all lived with the disappointment ever since.</p><p>All my life I hated myself<br>My self-esteem was legendary<br>My relationships, tragic<br>I knew I was ugly and unlovable.</p><p>I worked harder; my bloodied footsteps<br>Traced the path to the mountaintop<br>I can see their golden palace where they stare at death<br>Flakes of borrowed gold whirl and eddy<br>Those portraits in the attic don’t look so good now</p><p>My own emotional blackmail hooks me<br>I should know better<br>I visited last year and once again became the ugly, embarrassing klutz<br>My golden body burned by their corrosive need to be<br>Those nice, sensible people who are always right</p><p>I won’t go back.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=b998a4414abd" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Cake or Death?]]></title>
            <link>https://medium.com/@doctor_27995/accept-my-lot-88296de6d51a?source=rss-5cdabe6c0e18------2</link>
            <guid isPermaLink="false">https://medium.com/p/88296de6d51a</guid>
            <category><![CDATA[society]]></category>
            <category><![CDATA[life]]></category>
            <category><![CDATA[health]]></category>
            <dc:creator><![CDATA[Helen R]]></dc:creator>
            <pubDate>Sun, 14 Jun 2026 17:09:06 GMT</pubDate>
            <atom:updated>2026-09-19T04:02:34.162Z</atom:updated>
            <content:encoded><![CDATA[<h3>Cake or Death? No hope or Bob Hope: Navigating the complacency and power dynamics of modern UK stroke pathways</h3><figure><img alt="" src="https://cdn-images-1.medium.com/max/395/1*2Amz3TGwxbfmdEDECItagA.jpeg" /><figcaption>I’m honestly happy with either….said no one, ever</figcaption></figure><p>Another rant here folks, and for once not about ADHD — although maybe my ADHD is exactly what makes me so outraged. This time we’re discussing the systemic fatalism, administrative complacency, and infantilising paternalism embedded within the secondary prevention pathways of the National Health Service (NHS) for stroke and Cerebral Small Vessel Disease (CSVD).</p><p>For those who don’t know me, I am a fit, active, slim (thanks Mounjaro) 61-year-old Consultant Psychiatrist, and since 16.4.2026 a stroke survivor. To be precise, a lacunar infarction.</p><p>Whaddyaknow, but the NHS stroke service — now that I am a user — operates on a huge clinical double standard. While contemporary cancer care rapidly synthesises and adapts to early-phase trial signals, continuously innovating with best practice, neurovascular medicine sits complacently behind anachronistic definitions and institutional inertia.</p><p>This systemic lack of curiosity forces a toxic power dynamic onto a vulnerable population, now also dehumanised apparently, with the order of the day being passive compliance disguised as “accepting your lot.” Well, those who know me know that I have never been one to accept my lot, either for myself or my ADHD patients. Well, not if there is an obviously better way.</p><p>Here is my self-directed, data-driven journey to bypass this institutional neglect via advanced home diagnostics and off-label therapeutics. I am arguing for a radical paradigm shift in stroke services that treats patients not as passive clinical objects, but as autonomous intellectual partners. Or at least as human beings for starters.</p><h3>An Existential Shift</h3><p>On the 16th April 2026, my reality fractured. While writing up my clinic notes after lunch, I suddenly lost the entire left side of my body for 90 minutes. Lying on the floor — fortunately, my partner called the ambulance — I was in a state of profound existential shock. One of my worst fears had happened. And worse: <strong>I wasn’t the clinician anymore. I was the patient.</strong></p><p>I could not believe this had happened when I thought I had everything under great control. My body completely came back as the paramedics lifted me upright for the trolley. Three hours later, after a clear CT scan, I was home from the regional stroke centre, having received world-class early stroke treatment; Atorvastatin and Clopidogrel (antiplatelet, blood thinner) for life, aspirin for 30 days, and a specialist follow-up under the NHS stroke pathway within the week. Perfect.</p><p>My blood pressure had been a bit high, so on the way out I had the sense to ask the discharge doctor for antihypertensive treatment.</p><p>I went home assuming that the impressive machine which had dealt with my acute stroke would now investigate why a relatively healthy 61-year-old woman had just infarcted part of her brain and would aggressively reduce the chances of its happening again.</p><p>My first mistake was assuming my follow-up would be at that same elite regional hub.</p><p>What they completely failed to mention was that this follow-up would not take place at their hospital. Instead, my care was dumped onto my local hospital — an institution that just happens to be a absolute byword for terrible inadequate care within the NHS and a place I and my family have avoided for years.</p><h3>Urgent Follow-Up: A Hollow Joke</h3><p>A week later, I’m sitting in a drab, clinical corridor, waiting to see the rudest doctor I have ever met, professionally or personally. No eye contact. No engagement with my questions. Refused to look at the home blood-pressure data I had brought. She told me:-</p><p><em>I’m the consultant </em><strong><em>(she was not a consultant)</em></strong><em>. You’re not (</em><strong><em>actually I am</em></strong><em>). This is my clinic (</em><strong><em>OK I’ll give you that one</em></strong><em>). I know what you need. You don’t (</em><strong><em>100% wrong</em></strong><em>)</em></p><p>The silent nurse chaperone told me that this doctor was under performance management, presumably for good reason. I actually felt sorry for her and styled my complaint as professional input re inadequate pathway design, assuming she had been put there by management as a way of throwing her under the bus (we call it managing out by patient complaint). I hadn’t yet realised my stroke made me officially subhuman.</p><p>Eventually an MRI was ordered. So this clinical pathway drags an acutely post-stroke patient to attend a pointless medical appointment, then make their own way to the MRI dept on the other side of the hospital, no escort, then back to see the same rude doctor? I could do it, but I have no idea how anyone disabled or impaired a few days after a stroke would get there.</p><p>The MRI showed my lacunar infarction. I was pretty shocked — both by my damaged brain and the absolute realisation that I was on my own here, with no meaningful information about what happened next. No coherent timeline for cardiac investigation. No meaningful discussion of blood-pressure optimisation. No explanation of early recurrence risk. No discussion of recovery. Not even a blooming leaflet to tell me about the high recurrence risk in the first 30 days, or the vital, 3-month post-stroke brain repair and neuroplasticity window that is so incredibly important for tissue recovery.. At least my shock seemed to amuse her.</p><h3>The Empty Pathway</h3><p>Nothing to worry about, I did get a post-stroke clinic review appointment at the crap hospital for December. Seven months later, long after the critical post-stroke tissue-recovery window had already permanently closed.</p><p>Excellent.</p><p>I was starting to learn a terrifying lesson about the NHS stroke pathway: the moment you sustain a brain injury, you are stripped of your humanity, professional identity, rights and voice. Beneath the slick stroke pathways and the outward appearance of care, actual clinical care is non-existent.</p><p>If I had been a normal patient, I would have gone home to wait quietly for those seven months. I would have spent the most vital recovery window of my life with my blood pressure largely unmonitored and untreated, my brain silently (or not silently, no one cares either way) deteriorating.</p><p>Luckily, I am not a normal patient. I am quite attached to my brain. I had been researching intensively from the very day of the stroke to find out exactly why this had happened and what the best available treatment was. Long before I even sat in that corridor, I had already researched the latest evidence and emerging best practice and aggressively optimised my blood pressure myself.</p><p>And I discovered something else.</p><h3>My vascular risk was higher than I knew</h3><p>I don’t expect anyone to know that just having ADHD gives you an independent significant vascular and metabolic risk. Here’s a quick n dirty explainer re that, will write a separate piece as this is IMPORTANT</p><p><em>The elevated risk of cerebral small vessel disease (CSVD) and vascular dementia in adults with ADHD is increasingly recognized as a multi-system, structural vulnerability that extends well beyond traditional cardiovascular risk factors. Centrally, a strongly established epidemiological and genetic overlap exists between neurodivergent conditions and systemic structural connective tissue disorders, such as hypermobility spectrum disorder and Ehlers-Danlos syndromes. This “connective tissue phenotype” points to a fundamental alteration in the extracellular matrix and structural proteins — essentially acting like fragile “cling film” surrounding the vascular architecture. When applied to the cerebral microvasculature, this structural connective tissue variant yields inherent small vessel fragility, predisposing the deep, thin wall perforating arteries of the brain to shear-stress damage, blood-brain barrier leakage, and local neuroinflammation. This localized microvascular vulnerability is chronically exacerbated by the volatile, high-velocity hemodynamic forces typical of ADHD-related autonomic dysregulation and episodic sympathoadrenal surges, which can be further aggravated by long-acting psychostimulant therapy. Over time, the intersection of an structurally delicate vascular wall with hyper-reactive autonomic stress accelerates arteriolosclerosis, chronic cerebral hypoperfusion, and the microvascular brain damage that directly underpins cognitive decline, rendering proactive endothelial stabilisation entirely logical.</em></p><p>However there were a couple of things they should have known and told me about…</p><p>Firstly, I am HLA-B27 positive and have a history of uveitis and inflammatory disease. In 2018, I fought the male centric guidelines to get the best biologic treatment , at a time when many clinicians still believed that B27+ve status was good for you unless you had the kind of bone fusion that actually happens very late in women (Google still said it last time I checked).</p><p>Treatment was life changing, all my symptoms vanished. Back in 2018, the link between HLA-B27 and vascular issues was viewed through a macro-vascular, large-vessel lens. Any vascular risk was thought to be due to chronic high-grade inflammation (elevated CRP) accelerating standard, large-artery atherosclerosis over decades. Because my overall inflammation was well-suppressed on Humira, we all assumed my blood vessels were safe.</p><p>I thought I was ahead of the game, on biologic treatment and under a renowned rheumatology team.</p><p>I was pretty shocked to discover that around 2021-2022, there had been a massive paradigm shift in the molecular and epidemiological landscape.</p><p>Large cohort data tracking HLA-B27 associated conditions like uveitis) revealed a startling, statistically significant spike in stroke incidence among these young, otherwise fit patients, entirely independent of joint symptoms, spinal fusion, peripheral inflammatory markers or standard lifestyle risks.</p><p>For at least four years, rheumatology departments across the UK have had the data to actively warn the HLA-B27 positive individuals on their caseloads about this silent microvascular vulnerability, yet my team didn’t tell me.</p><p>After my stroke, I asked my rheumatologist why she didn’t tell me? Her answer, “You should have booked in to ask me??”</p><p>Splendid.</p><p>Not many words after that, as you might imagine.</p><h3>And Then There Was Pre-Eclampsia</h3><p>Secondly, there was another huge risk sitting in my medical history.</p><p>I had mild pre-eclampsia in May 2011 when my youngest son was born. There was already conclusive evidence linking this to permanent vascular fragility.</p><p>Four years before that, a landmark <em>BMJ</em> meta-analysis had shown that pre-eclampsia doubles a woman’s lifetime risk of ischaemic stroke.</p><p>The American Heart Association formally classified pre-eclampsia as an independent, permanent vascular risk factor in February 2011.</p><p>NICE Guideline CG107 had been active across the NHS since August 2010, explicitly mandating that women with my history be formally counselled on their elevated lifetime stroke risks before discharge, with a protocol-driven handover to primary care to prompt lifetime vascular surveillance.</p><p>Didn’t happen.</p><p>At the time, I wasn’t terribly focused on myself. My baby was in neonatal intensive care and needed open-heart surgery. He nearly died. My whole brain was focused on researching his condition and fighting for best care for him. Ironically one battle after his open heart surgery was to prevent the team from discharging him for “rehabilitation” to the dreadful local hospital now managing my stroke aftercare.</p><p>No one told me, and I did not have a moment to consider that I might need to also research whether my care team and GP were ignoring NICE guidelines and not telling me about my now serious lifelong vascular risk or monitoring my blood pressure / lipids. For life.</p><p>For fifteen years, a time bomb had been ticking in my brain. Because I was slim (thanks Mounjaro) and fit, with no standard cardiovascular risk factors, I had trundled along completely oblivious, assuming that since my GP was happy with my occasionally checked blood pressure — which was generally around 135/85 mmHg — it was fine. It wasn’t. My tissues required the strict, neuroprotective &lt;120/80 mmHg target mandated by contemporary trials like SPRINT, but the system had not bothered to tell me and I was left completely in the dark.</p><p>Tick, tick, tick…..</p><p>Not too many words there either…..</p><p>Post stroke, my GP did have the grace to admit it was pretty poor, and will look into getting a medical student to go through the caseload to identify women with pregnancy complications, so I guess the hole in my brain may not have been for nothing……</p><h3>If you want preventative care don’t wait for the NHS</h3><p>As an ADHD clinician, I am well aware that standard systems don’t cover much of what we need, either for treatment, or optimising our physiology hence my clinic based on me researching my patient group. Ultimately, of course, it was my own fault for not knowing I needed to check this specific vascular overlap. But y’know, I know a lot about ADHD care and I always know exactly what will help my patients best.</p><p>If I had been a rheumatologist, I can’t believe it wouldn’t have occurred to me to warn my B27+ve patients (a significant proportion of any rheumatology caseload) about emerging vascular risk.</p><p>If I was a GP knowing that all the women on my caseload who had had pregnancy related blood pressure/sugar issues were at very enhanced vascular risk, I feel like I would reach out and tell them.</p><p>And if I were a stroke physician I wouldn’t dismiss ground breaking research evidence, from my own colleagues at my hospital as “sniff statistically underpowered, can’t recommend it”.</p><h3>Not Looking Great for You, Doc</h3><p>Gotta be honest folks, I’m an optimist but researching my prognosis was kinda grim.</p><p>Let’s say it like it is. <strong>There is currently no established treatment that stops or reverses the underlying CSVD.</strong> A lacunar infarct on MRI means I have established Cerebral Small Vessel Disease (CSVD), an insidiously progressive disease of the brain’s small vessels, associated with accumulating white-matter injury, further lacunar infarction, gait and balance problems, cognitive impairment, dependency, vascular dementia and premature death. Standard antiplatelets and generic BP targets reduce conventional vascular risk, but are not a disease-modifying treatment for the underlying CSVD.</p><p>Longitudinal studies show progression of both imaging abnormalities and structural network damage, and that progression predicts cognitive deterioration and dementia. <strong>The rate and eventual clinical consequences vary between individuals, but CSVD is an ongoing disease process, and without a proven disease-modifying treatment the underlying pathology tends to accumulate. Truly terrifying…</strong></p><p>Not lying folks, I am deeply, structurally furious that I am looking at this avoidable outcome….</p><h3>Before You Book Dignitas…</h3><p>The Lacunar Intervention Trial programme is investigating two repurposed generic drugs; <strong>isosorbide mononitrate (ISMN)</strong> and <strong>cilostazol </strong>in CSVD</p><p>Mechanistically, the combination is elegant. CSVD involves endothelial dysfunction, impaired vasoreactivity, blood-brain-barrier abnormalities and small-vessel dysfunction. ISMN provides nitric-oxide signalling; cilostazol has antiplatelet and vascular/endothelial effects. Together, they don’t just lower pressure; the aim is to stabilise and repair the endothelial wall, targeting aspects of the small-vessel pathology itself.</p><p>LACI-2 was a Phase II feasibility trial, just looking at whether there was enough evidence of benefit to proceed to a definitive efficacy trial, with larger patient numbers.</p><p>But bloody hell, look at the signals, the results for their protocol are staggering. Incredibly, by combining two well-established, cheap generic drugs — Isosorbide Mononitrate and Cilostazol — layered on top of best medical therapy, the trial demonstrated an incredible 56% reduction in cognitive impairment, a dramatic reduction in physical dependency, and an adjusted hazard Ratio of 0.58 for composite clinical outcomes.</p><p>Luckily LACI-3 is currently expanding into a massive Phase III trial across major UK academic networks.</p><p>I mean this is big news for stroke experts right? Of course they’ll be rushing to tell their patients and offer them the chance to try this treatment?</p><h3>A Tale of Two NHS Pathways</h3><p>What stands out for me from the NHS stroke pathway is its profound lack of curiosity or care…and the refusal to implement research finding we have had for over a decade. In 2026, the standard NHS stroke pathway ignores the 2015 SPRINT protocol, apparently content to let CSVD patients drift along at dangerous BP levels because…..honestly I can’t imagine why primary and secondary guidelines haven’t been updated to support evidence-based aggressive, intensive monitoring and how clinicians on those pathways actually sleep at night.</p><h3>Time for a cunning plan</h3><p>Naturally, I looked at joining LACI-3. Then I looked at the odds. Only one in four participants receive both drugs.</p><p>Excellent for science, less so when thinking about MY brain crumbling…</p><p>And they are only recruiting 1300 patients, UK wide, so only 325 trial participants will get both drugs.</p><p>So I hem hem managed to start the protocol drugs myself.</p><p>Unlike the poor trial patients, who had to wait on average 76 days (inter quartile range (IQR) of 27–244 days before getting the medications) I was fully optimised by Day 14 post stroke. And doing extremely well…</p><p>Now I needed a stroke physician prepared to engage with what I had done.</p><p>How hard could that be?</p><p>Quick reminder. CSVD is in a condition where the critical post stroke window for endothelial repair and neuroplasticity peaks within the first 14 to 30 days. Even our 325 lucky patients randomised to both drugs have to wait nearly two and a half months for randomisation [LACI-3]. While this is the best the trial machinery can do under standard hospital operational limits, it can easily be seen (by me, for example) as a design failure that would be deemed a catastrophic, fatal delay in any cancer pathway. Not criticising the LACI docs, they are clearly gods among men, but some might say this delay means the system compromises its own data.</p><h3>Not Booking Dignitas Yet</h3><p>Unfortunately I was stuck in the rubbish hospital, not even a review till December. The NHS response to my very kindly worded complaint about the awful doctor was torturous guff, but did make it very clear that no one there knew anything or gave a flying fuck whether I lived or died.</p><p>Time to go went private.</p><p>The academic researchers running the UK’s advanced Small Vessel Disease trials do not have private practices, but the guy I found is a senior stroke consultant and direct colleague of theirs at the exact same regional academic stroke centre.</p><p>Excellent. Finally a medical peer. A stroke expert would obviously look at the evidence, engage with cutting-edge data, look at me, look at the fact that I was already tolerating treatment, and have an intelligent conversation about uncertainty versus risk. Of course this senior academic would understand my protocol completely and write to my GP saying how clever I had been and that I should absolutely continue with it.</p><p>Reader, this did not happen.</p><h3>I Wouldn’t Treat My Dog Like This</h3><p>The consultant I saw wasn’t openly rude. I was paying, after all. But he was profoundly dismissive, and uninterested. Also completely ignorant of the crucial HLA-B27 inflammatory link.</p><p>When I laid out my clinical rationale for wanting to continue the LACI protocol drugs I was already successfully taking — I was gobsmacked to hear him waffling defensively about avoiding side effects and the pilot being “statistically underpowered.”</p><p>The side effects argument was particularly fascinating given that I was sitting in front of him already taking the drugs without those side effects.</p><p>Not only did he know nothing about B27 vascular risk, he had the absolute gall to state that he could not recommend the treatment until the massive Phase III LACI-3 study wraps up years from now.</p><h3>You could not make this up</h3><p>The crowning moment came when I pointed out that, unlike him, I wasn’t necessarily in an ideal position to wait several years for the answer.</p><p>Wisely, he explained: “Life is a game. You play the best you know but sometimes you just have a bad hand.”</p><p>Splutter.</p><p>There is something exquisitely ironic about being told to accept your “bad hand” by the person who currently holds the power to improve it.</p><p>We could summarise the “consultation” as “<em>I’ll take your money but I will not lift a finger to help you,</em> <em>and furthermore I will use my power to ensure that you do not get the best treatment.”</em></p><p>Not happening chum, you will have to indulge your sadistic power lust on your other patients.</p><h3>To be fair (choke)</h3><p>I guess if you are not very bright, jealous of your colleagues and have zero empathy or imagination…..and crucially if it is not you or a family member in the hot seat, facing a catastrophic prognosis of vascular cognitive decline, it is probably easy to treat a patient’s brain and future as a statistic.</p><p>It is kinda Catch 22 that the bad hand I was facing in that moment, was the )zero) risk that this “stroke expert” would be managing my treatment journey. And about those odds, not helped if your care is managed by 3rd rate clapped out “clinicians” who ignore any and all evidence that standard treatments don’t reverse the underlying pathology.</p><h3><strong>Relax, it’s only the second commonest cause of dementia</strong></h3><p>Here’s something I didn’t appreciate before my stroke.</p><p><strong>Vascular dementia is the second commonest type of dementia after Alzheimer’s disease.</strong> UK datasets show that 40,000–50,000 people develop vascular dementia each year in the UK, so at any time around 180,000 people are actively living with the condition. Risk basically doubles every five years, 1.7% of 65–69 years, 3.0% for ages 70–74, 6.0% for ages 75–79, and 11.1% between ages 80–84, increasing to nearly 30% for age 90–94.</p><p>And what is the commonest pathology underlying vascular cognitive impairment and vascular dementia? <strong>Yup, Cerebral small vessel disease.</strong></p><p>But even that substantially understates the problem.</p><p>The neat diagnostic categories of “Alzheimer’s dementia” and “vascular dementia” aren’t neat at all. Mixed pathology is extremely common. Major reviews estimate that CSVD contributes to around <strong>45% of dementia</strong>, while a recent mechanistic review concludes that, once its contribution to mixed Alzheimer’s/vascular dementia is included, <strong>CSVD probably contributes to more than half of all dementia cases</strong>.</p><p>Let that sink in for a moment. We have <strong>no established disease-modifying treatment for the small-vessel disease. And we</strong> are talking about a disease process implicated in <strong>something approaching half — and potentially more than half — of dementia</strong>, as well as around a quarter of strokes.</p><h3>What If It Were Cancer?</h3><p>I keep wondering how differently this conversation would happen if cerebral small vessel disease were cancer. Would we still say :-</p><p><em>Interesting. Wait 5 years for Phase III and don’t tell the patients</em></p><p>Seriously? I doubt it. Because cancer patients are understood to be people with something precious to lose. Their fear of progression matters. Their appetite for risk matters. Their priorities matter. Waiting has a cost, and they are entitled to decide how much uncertainty they are prepared to tolerate. Stroke patients somehow seem to lose some of that humanity.</p><p><strong>But cancer patients don’t have time to wait. Every bit of life is infinitely precious.</strong></p><p>Well, listen up. <strong>Neither do we. My brain isn’t waiting for Phase III.</strong></p><p>If this were cancer, surely the conversation would be:</p><p><em>“A randomised Phase II trial of two cheap, already licensed drugs has produced the first genuinely exciting therapeutic signal in this disease: less cognitive impairment and dependency and better quality of life, without a significant safety signal. We don’t yet know whether those benefits will be confirmed in the definitive trial. These drugs are pretty safe, of course like all drugs they have risks and contraindications, which we can discuss. But would you like to try them now or would you prefer to wait 5 years?”</em></p><p><strong>That is shared decision-making and informed consent. </strong>And most importantly, <strong>that treats the patient as a human being. </strong>Why should having a stroke make me less than human?</p><p>Is it ironic that this treatment is far cheaper than typical new cancer pathway drugs. There is absolutely no need for the National Institute for Health and Care Excellence (NICE) to agonise over health economics here. Without even considering the astronomical long-term cost of managing institutionalised vascular dementia, which completely eclipses the negligible cost of early-stage informed opt in use of these two generic drugs.</p><h3>Cake or Death folks</h3><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*3kjOueRZ-58WQiHuQvFY3g.png" /><figcaption>Are you seriously choosing the blue treatment?</figcaption></figure><p>Anyone remember <a href="https://www.youtube.com/watch?v=PVH0gZO5lq0">Eddie Izzard’s <em>Cake or Death?</em> </a>sketch? It works because the choice is absurdly simple: nobody chooses death when cake is available.</p><p>Well, look at that graph, constructed from the published LACI-2 results. Yes, these were Phase II efficacy signals and need replication. But they have to be considered against a disease whose consequences include cognitive impairment, dependency and vascular dementia. At 12 months, cognitive impairment occurred in <strong>46.7% receiving both drugs compared with 65.4% receiving neither</strong>, while dependency was <strong>5.4% versus 17.7%</strong>.</p><p>You can call that a possible statistical fluke. Fine. But seriously: if this were you, somebody showed you these results, explained their limitations and made sure you understood them, <strong>would you choose blue?</strong></p><p>I wouldn’t. My stroke consultant wouldn’t. And I would be fascinated to know how many LACI investigators would choose those odds for themselves, their partners or their children.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*N4IJiHZXqKuDCrevE6oGnA.png" /><figcaption>You choose Doc, I’m easy either way, it’s only my brain after all …</figcaption></figure><p>Yet patients are apparently consenting to randomisation. Humans don’t agree to that bad of a choice, so we should question the consent process. Post-stroke populations have substantial rates of cognitive impairment. Genuine informed consent should mean showing prospective participants this graph, explaining clearly that the apparent benefit may be due to chance, giving them sufficient time and support to understand that uncertainty, and then asking whether they would choose both drugs or accept a 75% probability of not receiving the combination.</p><p>We are scientists. Let’s test it. Show the graph to prospective participants, check comprehension and record how many would choose randomisation if both drugs were available to them. Then ask the investigators the same question about themselves and their families.</p><p>Because randomised trials depend upon clinical equipoise: genuine uncertainty within the expert community about which treatment is preferable. And looking at these data, I do not believe meaningful equipoise still exists. I simply do not believe that anyone who understood these results would accept those odds for their own brains or those of the people they love.</p><p>We may love science, but we all love our brains more.</p><p>And, of course, these are the lucky ones. Most people with CSVD aren’t even being offered a 25% chance.</p><h3>So what does this mean for UK CSVD patients?</h3><p>Hate to break it to you folks, but even if LACI-3 achieves full data lock and successfully proves these statistics over its planned runway, the bureaucratic machinery of NICE and the National Clinical Guideline for Stroke will take a further 12 to 24 months to formally update their manuals.</p><p>For an ordinary patient sitting in an NHS clinic today, the realistic wait for this protocol to be officially adopted as standard best practice is closer to 2030 or 2031. Given that they are already ignoring best practice guidelines from 2015 about safe blood pressure management, suspect holding the breath is not a good plan.</p><p>Even if they adopted it immediately after Phase 3 (assuming results similarly positive, no chance I would say as we’re still waiting for SPRINT from 2015), expecting a patient with active subcortical ischemia to wait four to five years for a promising looking, safe looking, dirt-cheap treatment is not “sensible care” — it’s the equivalent of a giant finger for the 40–50,000 UK patients living with CSVD. Safe, well-tolerated inexpensive medications are withheld under the excuse of conservative guideline-adherence. Because the “statistically powered”, 1,300-patient LACI-3 trial is actively running right now across the UK, apparently stroke consultants think it is just fine to treat the incredible pilot data as non-existent till 2030. Thanks guys I feel seen and cared for…And also thanks for respecting my choice to take a safe bet for my brain (not)</p><h3>N=1 (again)</h3><p>One (this one anyway) has a question. if these staggering neuroprotective signals can be achieved when the drugs are delayed by months, what could be achieved if a patient received the full protocol within 14 days of their stroke? They call it an N-of-1 trial, folks. By managing my own protocol, I have bypassed the 79-day administrative lag entirely, placing my microvasculature onto the protocol during the absolute peak of its cellular repair window. I will keep you posted with my results but I am feeling optimistic.</p><h3>Still not booking blooming Dignitas yet (sorry NHS)</h3><p>The current NHS secondary stroke pathway is an institutional tragedy masquerading as comprehensive care. It is a system that recruits third rate clinicians, relies on anachronistic definitions, hides behind statistics, and relies on hollow pathways and a dehumanising power differential largely ignoring a highly vulnerable population.</p><p>Unfortunately for some, my brain is working extremely well and I am outraged, not so much for me, I have always had to look out for myself, but for my fellow stroke patients, a dehumanised and often cognitively impaired group who must blindly trust this absolute shower with their “care”.</p><p>Judging from my recent experience, very few CSVD patients are getting anything resembling the best available treatment. The only UK CSVD patients receiving optimised microvascular care right now are me, the 325 patients randomised into the dual-drug arm of the LACI-3 trial (given late though), and perhaps a few rare individuals who have the agency to see innovative, academic private clinicians…</p><p>I will absolutely not be accepting rubbish care, systemic neglect and institutional gaslighting. I refuse to “be sensible and accept my lot”, and I refuse to dement quietly. Because the NHS pathway failed me, I took control of my own clinical governance and started the recommended LACI treatment framework. Today, my blood pressure is perfectly controlled at &lt;120/80 mmHg, I am entirely asymptomatic, thriving and still running my ADHD clinic. Not cognitively impaired then.</p><p>I have now found a progressive private specialist who has the mental resources to look at the data, and the empathy to understand that pretty much anyone in my position who understood the data would want this chance (DM me if you want an intro). As my friend says “you have two hopes, no hope and Bob Hope…” It makes sense to choose Bob.</p><p>My hope is that my optimised vascular management — combining the targeted LACI mechanism with state-of-the-art metabolic and endothelial stabilisation via my Metformin and Mounjaro (Tirzepatide) microdose stack, alongside my regular anti-inflammatory Humira (Adalimumab) therapy — means that I will not have to worry about vascular dementia for many years yet, if at all. I am actively changing my own trajectory. After all, someone has to stick around to optimise all those ADHD patients who are currently being managed so outrageously by a different broken bit of the system.</p><h3>References</h3><ul><li>SPRINT Research Group (2015). <em>A Randomized Trial of Intensive versus Standard Blood-Pressure Control.</em> New England Journal of Medicine, 373(22), 2103–2116.</li><li>Tsung T, Huang K-H, Chien W-C, Chen Y-H, Yen I-C, Chung C-H, Chen J-T and Chen C-L (2022) Uveitis increases the risk of stroke among patients with ankylosing spondylitis: A nationwide population-based longitudinal study. Front. Immunol. 13:959848. doi: 10.3389/fimmu.2022.959848</li><li>LACI-2 Trial Investigators (2023). <em>Effects of Isosorbide Mononitrate and Cilostazol on Clinical Outcomes in Ischemic Stroke: The LACI-2 Randomized Clinical Trial.</em> JAMA Neurology, 80(7), 690–700.</li><li>Wardlaw, J. M., et al. (2024). <em>The Lacunar Intervention Trial-3 (LACI-3): Protocol for a Large-Scale Phase III Trial Assessing Long-Term Cognitive and Vascular Outcomes in Cerebral Small Vessel Disease.</em> International Journal of Stroke, 19(2), 145–154.</li></ul><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=88296de6d51a" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Κάθαρσις — Mother’s Day 2026]]></title>
            <link>https://medium.com/@doctor_27995/%CE%BA%CE%AC%CE%B8%CE%B1%CF%81%CF%83%CE%B9%CF%82-mothers-day-2026-e2a065053617?source=rss-5cdabe6c0e18------2</link>
            <guid isPermaLink="false">https://medium.com/p/e2a065053617</guid>
            <category><![CDATA[family]]></category>
            <category><![CDATA[life]]></category>
            <category><![CDATA[motherhood]]></category>
            <category><![CDATA[this-happened-to-me]]></category>
            <category><![CDATA[poetry]]></category>
            <dc:creator><![CDATA[Helen R]]></dc:creator>
            <pubDate>Sun, 15 Mar 2026 14:48:25 GMT</pubDate>
            <atom:updated>2026-04-01T07:11:26.614Z</atom:updated>
            <content:encoded><![CDATA[<p>I was born blue<br>You held me and promised me<br>everything</p><p>Years later<br>I promised you a castle</p><p>Eight years old — <br>already trying to repair<br>a broken kingdom</p><p>Back then I believed promises were tools<br>that fixed the world<br>It seems<br>we both lied</p><p>You taught me everything you knew.<br>books, stories,<br>my father’s betrayal,<br>all the strange, wild things in your mind<br>I sometimes think I remember your life better than my own<br>I drank greedily</p><p>Then I kept going<br>into places<br>you could not enter<br>my father’s world</p><p>You hated me for that</p><p>“I’d rather you were dead<br>than not in touch with me”</p><p>When was the first betrayal?</p><p>You tried to keep me close with anger,<br>You had a genius for it<br>the hook in the flesh</p><p>Always the same question<br>slipping quietly under the door:</p><p>Are you a member of this family or not?</p><p>I was always the villain — <br>destined to grow up and join my father<br>the evil priest of Atlantis<br>who drowned a continent<br>to spite his family<br>I couldn’t wait</p><p>You fought to keep me with you<br>the more you pleaded and cursed <br>the more I struggled<br>a drowning child</p><p>You wanted my anger<br>to turn outward and send tsunamis <br>against your enemies<br>but I saw the threads<br>and my anger drowned you</p><p>We fought all our lives<br>our phone calls were treacherous pools<br>I wanted to stay<br>but you were always pulling me down<br>toward the lost city<br>dark tangles, rage and hate<br>You always wanted me dead</p><p>No treaty was possible<br>between the sea’s stormy caverns <br>and the castles</p><p>I fought you for my life<br>the slammed receiver<br>the words I never meant to say</p><p>except that I must have meant them<br>because they came out</p><p>Mother, I wanted to tell you something<br>I kept my promise<br>I built the castle<br>but you would not live there with me</p><p>Also, I don’t think my father pulled the plug<br>on the whole continent<br>your kind have always lived in the sea<br>dragging men down with murderous love<br>and raging when they break free</p><p>After the last call<br>there was only silence</p><p>One evening my sister called <br>to say you were dead<br>and burned<br>Your instructions</p><p>I stood there holding the phone<br>remembering you once telling me</p><p>that when I was born<br>blue and fragile<br>you held me<br>and promised me<br>everything</p><p>You live in my castle now<br>strangely quiet, but still sad<br>maybe after all it was me who wanted you dead?<br>you certainly are easier to live with now<br>your death has diminished you<br>but changes nothing</p><p>I miss only<br>what I always missed</p><p>RIP Stella 1942–2018</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=e2a065053617" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[ADHD treatment, see our phenotype don’t moralise our biology]]></title>
            <link>https://medium.com/@doctor_27995/adhd-treatment-see-our-phenotype-dont-moralise-our-biology-bf916f3b0277?source=rss-5cdabe6c0e18------2</link>
            <guid isPermaLink="false">https://medium.com/p/bf916f3b0277</guid>
            <category><![CDATA[lifestyle]]></category>
            <category><![CDATA[politics]]></category>
            <category><![CDATA[mental-health]]></category>
            <category><![CDATA[society]]></category>
            <category><![CDATA[psychology]]></category>
            <dc:creator><![CDATA[Helen R]]></dc:creator>
            <pubDate>Sun, 01 Mar 2026 10:56:27 GMT</pubDate>
            <atom:updated>2026-03-02T23:35:08.461Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*Z2vwN94cVIPS9JEp4xbIYg.png" /><figcaption>Imagine, you can get metformin at the pharmacy there….</figcaption></figure><p>ADHD is often reduced to a narrow, behavioural “psychiatric disorder” defined by deficit and non-compliance. However, when viewed through a multisystemic clinical lens, the ADHD phenotype can be clearly seen as a complex neuro-metabolic-autonomic divergence.</p><p>Failure to understand these systemic differences leads to what is effectively “medical gaslighting,” where physiological imbalances are mislabelled as character flaws (laziness, greed, or drug-seeking), and essential, low-cost biologic stabilising treatments (like metformin, magnesium, or clonidine) are denied.</p><p>From a UK perspective, the NHS access pathway functions like an executive-function trap even before you can get an appointment. It combines this with lack of phenotypic awareness and inappropriate threshold-based gatekeeping of essential biologic stabilisation at GP level to amplify shame and prevent or delay effective treatment. Let’s look at how they do it on Planet ADHD, and why the clinical lever is not more diet lectures, but proactive physiological scaffolding.</p><p>Planet ADHD uses a common-sense, adult-partnership model: reduced inappropriate blood test barriers for low-risk, biologically stabilising medicines. It is designed for executive dysfunction; and treats hormonal, autonomic, histaminergic and metabolic stabilisation as foundational care. None of this was ever about willpower or moral virtue, but unrecognised phenotypic physiology. Planet ADHD is not a real place sadly, but a thought experiment I designed out of frustration at the unnecessary barriers our system places at every stage for ADHD-ers. Even before we try to get a diagnosis and actual stimulant.</p><h3>The multisystemic ADHD phenotype</h3><p>The multisystemic ADHD phenotype is a complex neuro-metabolic-autonomic divergence that is mischaracterised as a behavioural disorder when viewed through a standard Neurotypical (NT) medical lens. At its core, this phenotype involves a “hungry brain” prone to cerebral hypometabolism due to faulty glucose transport (GLUT3/SLC2A3).</p><p>Where the NT lens sees “laziness” or sugar-seeking “greed,” the physiological reality is a cellular energy crisis requiring metabolic priming with metformin to prevent executive collapse. This is coupled with a hyper-reactive locus coeruleus that produces a high-baseline “noisy” sympathetic tone; while often misdiagnosed by NT medicine as generalized anxiety or personality disorders and treated with ineffective SSRIs, this actually represents an autonomic instability that requires a central “dimmer switch” like clonidine to manage the physiological surge of norepinephrine and rejection sensitive dysphoria (RSD).</p><p>Furthermore, this phenotype is deeply integrated with connective tissue laxity (hEDS/HSD), where “stretchy” collagen results in a dysautonomic “boggy gut” and orthostatic intolerance. While NT clinicians may dismiss these as “somaticising” or psychosomatic due to normal blood tests, stimulants like Lisdexamfetamine (LDX) actually serve as essential autonomic hardware — acting as prokinetics for the gut and providing functional “muscle armour” for unstable joints.</p><p>This systemic vulnerability is exacerbated by neuroendocrine sensitivity, particularly in females, where the luteal phase drop in progesterone creates a catastrophic GABA-A deficit that renders dopaminergic meds ineffective — a failure of regulation often dismissed as “mere” PMS.</p><p>Finally, the phenotype frequently involves mast cell instability (MCAS), where high histaminergic “static” drives chronic neuro-inflammation and nocturnal arousal. By mistreating these as isolated allergies rather than systemic drivers of brain fog, the NT model denies patients the essential H1/H2 blockade needed to stabilise their entire physiological scaffold. This is everyone in my ADHD clinic. But unless you ask the questions, you won’t see it.</p><h3>The moralisation of physiology</h3><p>A striking pattern in ADHD clinics is the internal narrative patients carry. weight gain = greed. Fatigue = laziness. Blood pressure drift = weakness. Patients conceptualise physiology as poor self-control.</p><p>This framing is deeply mismatched to the underlying biology. Years of sympathetic overdrive alter glucose handling, appetite signalling, sleep architecture, and inflammatory tone. Histamine reactivity can fragment sleep and increase adrenergic noise. Chronic executive strain increases reliance on rapid fuel and short-term coping. These are not moral defects; they are adaptive responses to a nervous system running at high gain.</p><p>Influencer culture reinforces this. It promotes high-intensity lifestyle regimens and dramatic optimisation sell courses and supplements, the more expensive, the better. The “If we were disciplined enough, we would meal-prep, strength-train daily, and meditate at dawn” narrative plays right into our self shame. Cheap, off-patent medicines do not generate affiliate income. The gulf between ideal and lived capacity widens shame. We dismiss ourselves before the system even gets the chance to dismiss us.</p><p>The correct response to yet another patronising diet sheet should be a complaint that our doctor has not kept up with training. Instead we thank them and go home to cry. How do they do it better on Planet ADHD? Simples…..</p><h3><strong>Systemic Autonomic Restoration Protocol</strong></h3><p>This protocol represents a multisystemic strategy to manage the ADHD phenotype, specifically addressing the very frequently occurring high-comorbidity cluster of Postural Orthostatic Tachycardia Syndrome (POTS), Hypermobility Spectrum Disorders (hEDS/HSD), and Metabolic Dysregulation. Rather than treating ADHD as behaviour, this scaffold approach stabilises the underlying physiological and autonomic imbalances that frequently render standard dopaminergic monotherapy ineffective or poorly tolerated.</p><h3><strong>Step 1:</strong> <strong>Ionic and Neuromuscular Baseline</strong></h3><p>The first step involves establishing an ionic and neuromuscular baseline using titrated magnesium (ideally glycinate). This acts as a natural NMDA receptor antagonist and a cofactor for the GABA-A receptor, which increases the threshold for NMDA-mediated neuronal excitability and provides a GABAergic buffer, calming the brain and supporting sleep. Resolving systemic magnesium depletion — often exacerbated by chronic sympathomedullary activation — also mitigates the risk of stimulant-induced neuromuscular irritability, such as bruxism and tension, and provide a stable “electrical floor” for the nervous system.</p><h3><strong>Step 2: Histaminergic and Mast Cell Buffer</strong></h3><p>The second step provides a histaminergic and mast cell buffer through the combined use of fexofenadine (H1) and famotidine (H2). In the ADHD population, sub-clinical mast cell activation syndrome (MCAS) often drives nocturnal autonomic arousal and “silent” reflux, which manifests as chronic brain fog and disrupted sleep architecture. Stabilising the histaminergic system reduces the pro-inflammatory “static” that otherwise impairs cognitive clarity and sleep quality.</p><h3><strong>Step 3: Central Sympatholytic Dimmer</strong></h3><p>The third step introduces low-dose Clonidine. This does not function as a primary antihypertensive at these doses, but as a neuromodulator .Acting as an alpha-2A adrenergic agonist at the locus coeruleus, it stimulates pre-synaptic auto-receptors, and inhibits the tonic and phasic surge of norepinephrine. This stabilizes the autonomic nervous system (ANS), effectively improving sleep onset and architecture, and dampening RSD and sensory overstimulation and improving orthostatic hypotension (at clinic doses). On Planet ADHD, we consider low dose clonidine as a vitamin.</p><h3>Step 4 : Metabolic Energy Coupling and Neuroprotection</h3><p>The fourth step addresses Metabolic Energy Coupling and Neuroprotection using Metformin and Vitamin B12. Given that ADHD carries a twofold increased risk of Type 2 Diabetes, Metformin is utilised here to bypass cerebral insulin resistance and GLUT3 transport deficits. This ensures a consistent glucose supply to the prefrontal cortex, preventing reactive hypoglycaemia and the “executive collapse” common in the late afternoon. B12 is co-prescribed prophylactically to protect the myelin sheath and maintain metabolic cofactors.</p><h3><strong>Step 5: Ladies only, GABAergic Progesterone Floor</strong></h3><p>The fifth step, for female patients, establishes a GABAergic Progesterone Floor using Utrogestan (Micronised Progesterone). By providing a stable level of allopregnanolone — a potent positive allosteric modulator of GABA-A receptors — this intervention prevents the catastrophic “catamenial crash” of executive function during the luteal phase. It ensures that the ADHD neuro-metabolic shield remains intact when endogenous progesterone levels naturally plummet. This reduces sympathetic overdrive and supports deep, restful sleep, as well as stabilising the cycle.</p><h3>Step 6: <strong>Bupropion</strong> as a <strong>Catecholamine Primer</strong></h3><p>The sixth step utilises Bupropion as a catecholamine primer. As a sustained-release NDRI, it provides a steady, background “tonal” increase in dopamine and norepinephrine. This priming effect reduces the “peak-and-trough” volatility often associated with stimulant use, allowing the patient to remain functionally regulated between doses and decreasing the overall requirement for higher-dose stimulants which may add to the sympathetic overdrive, “fight/flight” which is often default in ADHD.</p><h3>Step 7: <strong>Precision Executive Function Layer</strong></h3><p>The seventh step layers a Precision Executive Function Layer using Immediate-Release (IR) Stimulants. Because the physiological scaffold is now stable — the autonomic “noise” is lowered, the glucose supply is steady, and the hormonal baseline is supported — the stimulant can act specifically on dopaminergic executive circuits. This reduces the language processing bottleneck in ADHD, with superior focus and task initiation, but with significantly reduced sympathetic overdrive.</p><h3>Step 8: <strong>Haemodynamic Hardware Fix</strong></h3><p>The final step provides a Haemodynamic Hardware Fix through the use of Medical Compression and Electrolyte-Fluid Management. In patients with connective tissue laxity, “stretchy” vasculature leads to peripheral blood pooling and reduced cerebral perfusion. By mechanically and osmotically supporting blood flow to the brain, we prevent the body from using a compensatory “anxiety surge” (norepinephrine) to maintain consciousness, thereby completing the restoration of systemic autonomic equilibrium.</p><h3>Gatekeeping and shame within the NHS</h3><p>On Planet ADHD, the system is designed for dignity and ease of access. The “common sense test” is applied to data which doesn’t make sense. Low-cost high benefit treatments such as statins, utrogestan and metformin are available at the pharmacy and encouraged for all who benefit, not gatekept behind expensive blood tests that deny treatment until we are sufficiently damaged. No one pretends that diets and discipline are effective treatments for metabolic disadvantage. No one thinks trauma causes sympathetic overdrive, or suggests therapy for it. Access is simple and the pharmacist can ask simple screening questions. Everyone has routine annual well person screening.</p><p>When can I go there?</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=bf916f3b0277" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[ADHD, Insulin Resistance….the fight to be seen (and treated) goes on…]]></title>
            <link>https://medium.com/@doctor_27995/adhd-insulin-resistance-the-fight-to-be-seen-and-treated-goes-on-48adbd0b9bb3?source=rss-5cdabe6c0e18------2</link>
            <guid isPermaLink="false">https://medium.com/p/48adbd0b9bb3</guid>
            <category><![CDATA[health]]></category>
            <category><![CDATA[life]]></category>
            <category><![CDATA[mental-health]]></category>
            <category><![CDATA[fitness]]></category>
            <category><![CDATA[society]]></category>
            <dc:creator><![CDATA[Helen R]]></dc:creator>
            <pubDate>Sun, 22 Feb 2026 09:13:10 GMT</pubDate>
            <atom:updated>2026-02-22T09:13:10.170Z</atom:updated>
            <content:encoded><![CDATA[<p>What if we should all be offered a cheap, safe treatment costing pennies a day to stabilise our physiology, help brain fog and extend our lifespan….</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*WvsfAxc5nYLwiHTwTfQ45Q.jpeg" /><figcaption>You already know you don’t deserve treatment…..the doctor will shame you now….</figcaption></figure><p>Research increasingly shows that adults with ADHD experience not only executive dysfunction and emotional volatility, but also sugar cravings, post-prandial sleepiness, energy crashes, central adiposity, brain fog, and a pervasive sense of physiological instability that often worsens with age. These features are routinely framed as lifestyle failure. Increasingly, they look like insulin resistance (IR).</p><p>Large registry and meta-analytic studies consistently demonstrate roughly a twofold increased risk of type 2 diabetes (T2DM) in adults with ADHD, persisting after adjustment for medication exposure. Yet even in these papers the tired narrative remains. You can read, in the same breath, that ADHD is linked to T2DM via shared dopamine–glucose biology, and then that the association is “<strong>“</strong><a href="https://psychiatryonline.org/doi/10.1176/appi.ajp.2015.15020266"><strong>is largely mediated by unhealthy lifestyle choices, including poor dietary habits (high consumption of processed foods and sugar-sweetened beverages) and low levels of physical activity, which are consequences of deficient self-regulation</strong></a><strong>”.</strong> While we’re at it, we can also get in a cheap swipe at ADHD medication: “<a href="https://mentalhealth.bmj.com/content/27/1/e301195"><strong>psychostimulants may potentially have hyperglycaemic effects</strong></a><strong>”</strong> (err they actually don’t).</p><p>Goddamn those greedy ADHD-ers: biologically vulnerable and morally defective, apparently. Really, greedy and lazy AND having increased metabolic risk — what are the odds of that? Methinks these researchers are wanting to have their cake and eat it. Perhaps they have ADHD as well?</p><p>Look, I know we don’t want to let lack of evidence get in the way of lazy biases, but this is clinically inconsistent and intellectually embarrassing. And funny how that poor control goes away for ADHD-ers just like it does for anyone else with these symptoms, when given metformin.</p><p>Just imagine the outcry if research attributed increased metabolic risk to greed/laziness in other whole groups such as people of Asian or African ethnicity — and then used that framing to justify delayed treatment. Noooo, it’s biology for them For ADHD it’s “deficient self-regulation.” I’m calling diagnostic overshadowing, discrimination and medical bias (again). What a disgrace.</p><h3>The Hunter Phenotype</h3><p>From an evolutionary perspective, ADHD neurobiology may reflect traits that were adaptive in environments of unpredictability and intermittent food availability: novelty-seeking, rapid threat detection, flexible reward-driven behaviour — useful in foraging ecologies. A tendency toward relative insulin resistance and energy storage during abundance may have buffered against scarcity. In a world of continuous food abundance and extended lifespan, that buffering becomes maladaptive.</p><h3>Stop calling us greedy</h3><p>Neuroendocrine mechanisms — not insulting platitudes — plausibly bridge ADHD and metabolic vulnerability. ADHD populations frequently show heightened sympathetic drive and stress-reactive HPA activity, which promote hepatic glucose output, visceral adiposity, and reduced peripheral insulin sensitivity. In modern conditions, that translates into glycaemic volatility and fatty-liver biology — not moral weakness. If we accept that reactive hypoglycaemia (the “crash”) and hyperinsulinaemia (the “fat-storage lock”) are biological drivers of hunger and exhaustion, then those symptoms are metabolic, not “behavioural,” regardless of whether the patient has ADHD or not.</p><p>It is clinically inconsistent to treat the metabolic symptoms of one high-risk group (e.g., patients of Asian heritage or with a family history of T2DM) as “metabolic” or “hormonal” while treating the same symptoms in ADHD patients as “behavioural.” This creates a <strong>discriminatory barrier to care</strong>. When a clinician tells an ADHD patient to “use more willpower” or “manage their executive function” instead of offering a metabolic stabiliser like metformin, they are effectively denying medical treatment for a biological dysfunction based on a psychiatric diagnosis.</p><h3>Even worse for ADHD women…what are the odds?</h3><p>The metabolic signal is present in both sexes, but in women it is often amplified by PCOS-spectrum physiology and then amplified again with perimenopausal shift from the late 30s onward, which further degrades insulin sensitivity and alters fat distribution. What are the odds eh?</p><h3>The False Binary: Starvation or Obesity</h3><p>In clinic, a pattern emerges rarely discussed publicly. Some high-conscientious ADHD adults maintain a “normal” BMI only through chronic starvation and sympathetic overdrive. The alternative is rapid weight gain with ordinary eating. Both are unstable states. Insulin resistance creates erratic fuel signalling; dopamine fragility amplifies reward-seeking under volatility; sleep loss worsens leptin–ghrelin imbalance. Appetite is neuroendocrine drive. To assume obesity equals greed ignores endocrine reality and collapses under clinical scrutiny. Many patients are exerting extraordinary effort simply to remain functional; others have oscillated for decades between restriction and rebound.</p><h3>Insulin Resistance as a Physiological Driver</h3><p>Insulin resistance is not a binary event that begins at HbA1c 6.5%. It is a progressive signalling failure. Peripheral tissues respond poorly to insulin; the pancreas compensates with hyperinsulinaemia; glucose clearance becomes unstable. When cellular uptake is inefficient, the brain experiences fluctuating fuel delivery as threat.</p><p>Sugar cravings are symptoms of biochemical urgency. Energy crashes reflect fuel-delivery mismatch: glucose may be present in the bloodstream but unavailable intracellularly; reactive dips follow post-prandial spikes and people feel lethargic after eating rather than satiated. “Brain fog” reflects unstable cerebral fuel flux: oscillation (spike, overshoot, crash) degrades cognitive clarity and executive reliability, compounding dopaminergic fragility. By the time HbA1c rises, the disturbance may be a decade old and the damage is often permanent.</p><h3>Why don’t we treat it before that happens?</h3><p>Great question. The greed narrative collapses in seconds under biological scrutiny. Metformin and GLP-1 drugs have already run the sociological experiment. When treatment quiets lifelong “food noise,” patients discover they have the same willpower as everyone else. Metformin stabilises hepatic glucose output and improves insulin sensitivity; patients often describe fewer crashes, reduced cravings, steadier weight and clearer cognition. These are metabolic stabilisers, not willpower dispensers. Shaming insulin resistance is as absurd as shaming hypothyroidism: a medieval category error, confusing signalling failure with moral failure.</p><p>But don’t worry, as ever medical research shows us how wrong we are, just greedy and lazy after all. But before you go too crazy with I told you so….</p><h3>Research doesn’t pass the common sense test</h3><p>Dr Google informs me that doctors don’t prescribe metformin because “, metformin “lost” to lifestyle (diet and exercise) in the <a href="https://www.niddk.nih.gov/about-niddk/research-areas/diabetes/diabetes-prevention-program-dpp">landmark DPP study</a> (58% vs 31% risk reduction) and of course “Doctors generally prefer the “most effective” intervention first, which is lifestyle modification, as it addresses the root cause of metabolic dysfunction without medication side effects” Excellent, don’t worry about me then doc we both know I’m just greedy and lazy…</p><p>Ahem common sense alert here. Given that cravings, crashes, fatigue and obesity are caused by metabolic difficulties, and those of us in the real world know that overweight people never do lose the weight for long, but often cycle between starvation and rapid weight regaining, it is obviously ridiculous to claim that lifestyle change works better than actual treatment.</p><p>A closer look at these metabolic studies shows us our common sense intuition — that the “lifestyle vs. metformin” study must be biased or incomplete — is 100% bang on right. Look closely at the longer term effects and we can see that (a) lifestyle effects fade with time and weight regain is common, and (b) biology fights back hard against diet-only weight loss via appetite upshift and metabolic adaptation.</p><h3>Biology vs. “Willpower”</h3><p>Guys a metabolically stable person doesn’t want to eat cake all day. When a person loses weight via diet alone, their body triggers <strong>metabolic adaptation</strong>: ghrelin (the hunger hormone) increases, and leptin (the fullness hormone) decreases. For every <strong>1kg</strong> of weight lost, resting metabolism drops by about <strong>20–30 calories</strong>, but appetite increases by approximately <strong>100 calories</strong>. So if you lose 10kg, you are fighting a <strong>1,000-calorie-per-day</strong> biological urge to eat, while your body is burning <strong>300 fewer calories</strong> than before. This “gap” is why almost everyone eventually regains the weight — and often more — as the body over-compensates to ensure it survives the “next” famine. Some effective intervention…..</p><h3>“Symptom vs. Driver” Flaw</h3><p>Our doctors harrumphing about lifestyle are treating obesity as the <em>cause</em> of insulin resistance. However in reality it is a <strong>feedback loop. </strong>If you have high circulating insulin levels, your body is biologically locked in “storage mode.” Trying to lose weight without lowering that insulin (via metformin or similar) is like trying to empty a bathtub while the tap is still running at full blast.</p><p>So I think we should all be able to agree that the “either/or” choice seen in studies should not dictate treatment. Using metformin to achieve <strong>glycaemic stability</strong> provides the biological foundation needed for <strong>lifestyle changes</strong> to actually stick. Obviously….</p><h3>So what are we waiting for???</h3><p>UK practice remains largely glucose-threshold driven. HbA1c is the gatekeeper: metformin arrives once pre-diabetes/diabetes is biochemically established (or in selected PCOS cases). That is biologically late. HbA1c is a lagging indicator. It reflects the outcome of metabolic strain, not the strain itself. A patient can maintain “normal” glucose while requiring pathological levels of insulin to do so. Chronic hyperinsulinaemia is not benign. It drives fat storage, inflammatory signalling, and the very crashes that make “lifestyle advice” so patronising and biologically illiterate.</p><p>Waiting for HbA1c to rise is like waiting for your house to collapse before fixing cracks. It is arguably negligent and certainly tragic in symptomatic patients from high risk populations.</p><h3>Treat the patient not the blood test</h3><p>In most areas of medicine, we treat suffering. In metabolic health, we often treat numbers. Post-prandial somnolence, reactive hypoglycaemia patterns, cravings and crash-cycles are not “willpower issues”; they are clinical symptoms of glycaemic instability — biological data. A monitored trial of a safe, low-cost medication in a symptomatic, high-risk patient is not reckless; it is proportionate. If crashes resolve and cognitive steadiness improves, that is clinically meaningful data; if not, the medication can be stopped. We already treat PCOS and perimenopause on symptoms, not blood tests. We treat asthma by response. We treat depression by trial of therapy. The ethical barrier should not be higher for metabolic stabilisation than for any other endocrine correction.</p><h3><strong>How should we assess risk of metabolic harm?</strong></h3><p>Risk for Type 2 Diabetes (T2DM) should be assessed cumulatively — genetics, medical history, physiological symptoms, and established risk categories. Relative risk is additive. Someone who sits in multiple high-risk groups (for example ADHD plus PCOS, or ADHD plus obesity and family history) carries compounded metabolic burden long before HbA1c crosses a diagnostic threshold.</p><ol><li>Clinical markers already recognised as high risk include pre-diabetes (5–10× risk, 5–10% annual progression), obesity (7–12× risk), severe obesity (up to 40–80× risk depending on age and distribution), and metabolic syndrome (~5× risk).</li><li>Several medical conditions reflect chronic hyperinsulinaemia even when glucose appears “normal”: ADHD (~2–3× T2DM risk), PCOS (3–4× risk), gestational diabetes (7–10× lifetime risk), and NAFLD (2–3× risk).</li><li>Genetic and demographic factors further lower the threshold for failure: one affected parent (2–3× risk), both parents (5–6×), certain ethnic backgrounds (2–4× risk at lower BMI), and increasing age.</li><li>Lifestyle stressors such as sedentary behaviour and smoking add incremental risk — but they operate on top of underlying biology, not in isolation.</li></ol><p>When a patient presents with metabolic symptoms — crashes, cravings, post-prandial somnolence, central adiposity — and belongs to several of these categories, progression risk is not theoretical. It is statistically substantial. In that context, early metformin is not indulgence; it is risk reduction.</p><h3>What is the fuss about metformin?</h3><p>Metformin is one of the most extensively studied, safest, and least expensive drugs in modern medicine. Its reputation rests not on hype, but on outcome data.</p><ol><li>In diabetes prevention, multiple large trials show consistent benefit. In the Diabetes Prevention Program (DPP), metformin reduced progression from pre-diabetes to type 2 diabetes by 31% over nearly three years. Long-term follow-up (DPPOS) demonstrated durable effect, with sustained risk reduction over 10–15 years and delayed diabetes onset. Similar benefit has been replicated internationally, including in the Indian Diabetes Prevention Programme. Meta-analyses of randomised trials show pooled risk reductions in the 30–40% range. This is not marginal.</li><li>In PCOS, metformin improves insulin sensitivity, reduces androgen excess, restores menstrual regularity, supports ovulation, improves lipid profiles and blood pressure, and reduces progression to diabetes. It is already accepted as a metabolic stabiliser in that context.</li><li>Mechanistically, metformin reduces hepatic glucose output, improves peripheral insulin sensitivity, and dampens glycaemic volatility. It lowers cumulative hyperinsulinaemia — the driver of NAFLD, vascular dysfunction, beta-cell strain, and systemic inflammation.</li></ol><h3>How might this translate to ADHD populations?</h3><p>If insulin resistance contributes to post-prandial somnolence, reactive hypoglycaemia, cravings, central adiposity and cognitive fog, then stabilising insulin signalling should reduce those symptoms. Clinically, many patients report fewer crashes, reduced sugar urgency, steadier energy, and more sustainable weight regulation. Rather than acting as a weight-loss drug, metformin functions as a metabolic equaliser, making lifestyle change biologically achievable rather than psychologically punitive.</p><p>There is emerging evidence that metformin may also reduce depressive risk and neuroinflammatory burden, with potential downstream effects on cognition and executive function. At minimum, preventing progression to diabetes reduces microvascular complications and long-term cardiovascular risk — outcomes that matter profoundly in ADHD populations already carrying elevated metabolic burden.</p><p>In short: metformin reduces progression to diabetes, stabilises metabolic physiology, and carries a six-decade safety record. It is an all round brilliant drug for anyone with metabolic symptoms. The question is not whether it works, but why we reserve it for biochemical failure rather than physiological instability.</p><h3>Why medicine is slow to change</h3><p>Despite the logic of early metabolic stabilisation, most clinicians remain bound by glucose-threshold guidelines (NICE in the UK, ADA in the US) that prioritise HbA1c over physiology. Treatment is triggered by biochemical failure rather than by symptomatic strain. Hyperinsulinaemia with “normal” glucose is rarely measured and even more rarely treated. The result is a glucose-centric system that intervenes late.</p><p>Two forces sustain this model. First, residual moral bias: a lingering belief that medication is the “easy way out” and that patients should “earn” metabolic health through discipline. Second, risk asymmetry: doctors are generally blamed for harm from prescribing more than harm from refusing to prescribe, especially if a treatment is “off license” ie not in the guidelines. Medico-legally it is safer to ignore the slow-motion vascular and beta-cell damage of chronic hyperinsulinaemia.</p><p>There is also an equity problem. Private precision medicine and longevity clinics (and my ADHD clinic) are starting to do this. Patients able to self-fund specialist metabolic care increasingly receive symptom-led trials of metformin, while everyone else must wait for the permanent damage point when diagnostic thresholds are finally crossed.</p><p>A cheap, safe, extensively studied drug with genuine transformational power becomes gatekept by a late biomarker.</p><h3>In the future it may become ethically difficult to justify not offering metformin to a symptomatic, high-risk patient. Yay</h3><p>However the paradigm is starting to shift from “glucocentrism” to cellular energy and insulin signalling. As insulin assays and longitudinal data mature and shared neuro-metabolic architecture between dopamine and insulin becomes clearer, behavioural blame will collapse. Ignoring compensatory hyperinsulinaemia will become increasingly difficult for doctors to defend.</p><p>Cost-benefit logic supports this shift. It makes little sense to require expensive assays to justify a low-cost drug with a six-decade safety record when the alternative is years of cumulative metabolic strain. The gate should be proportionate to the risk.</p><p>In the future, offering metformin to a symptomatic high-risk patient will be standard preventative care, and ADHD-ers will no longer be blamed for their physiology, but will take their rightful place alongside those who should be offered it.</p><p><strong>Research</strong></p><ol><li><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC1282458/#:~:text=The%20Diabetes%20Prevention%20Program%20(DPP)%20was%20a%2027%2Dcenter,already%20been%20reported%20(2).">The Diabetes Prevention Program (DPP)</a></li><li><a href="https://www.sciencedirect.com/science/article/pii/S0149763423000453#:~:text=Highlights,risk%20playing%20a%20smaller%20role">The association between type 2 diabetes and attention- deficit/hyperactivity disorder: A systematic review, meta-analysis, and population-based sibling study</a></li><li><a href="https://www.sciencedirect.com/science/article/pii/S2214623723000066#:~:text=Some%20studies%20have%20shown%20that,their%20high%20morbidity%20and%20mortality">Association of ADHD symptoms with type 2 diabetes and cardiovascular comorbidities in adults receiving outpatient diabetes care</a></li><li><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10227470/#:~:text=Results,association%20between%20ADHD%20and%20T2DM.">Roles of obesity in mediating the causal effect of attention-deficit/hyperactivity disorder on diabetes</a></li><li><a href="http://Metformin can help youth manage weight gain side effect of bipolar medications">Metformin can help youth manage weight gain side effect of bipolar medications</a></li></ol><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=48adbd0b9bb3" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Why do 5% of humans have ADHD?]]></title>
            <link>https://medium.com/@doctor_27995/why-do-5-of-humans-have-adhd-8001dd713957?source=rss-5cdabe6c0e18------2</link>
            <guid isPermaLink="false">https://medium.com/p/8001dd713957</guid>
            <category><![CDATA[psychology]]></category>
            <category><![CDATA[life]]></category>
            <category><![CDATA[self-improvement]]></category>
            <category><![CDATA[humor]]></category>
            <category><![CDATA[social-media]]></category>
            <dc:creator><![CDATA[Helen R]]></dc:creator>
            <pubDate>Wed, 04 Feb 2026 16:17:11 GMT</pubDate>
            <atom:updated>2026-02-04T16:17:11.782Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*PqRdGl4x79LsCtktOej2Hg.png" /><figcaption>And when are we going to start treating phenotypically??</figcaption></figure><p>Attention Deficit Hyperactivity Disorder (ADHD) is conventionally conceptualised as a neurodevelopmental disorder of attention and executive control. However, in adult clinical populations — ADHD does not travel alone. Instead, it is repeatedly embedded within a broader pattern that includes sensory overload, autonomic lability, hormonal sensitivity (women), connective-tissue-leaning features, immune and histamine reactivity, metabolic vulnerability, increased muscle tension, and difficulties with interoception and emotional labelling. These features recur with striking consistency, even in individuals who do not meet strict thresholds for hypermobility syndromes or overt dysautonomia on standard screening tools and is particularly noticeable among women presenting in midlife.</p><h3>The High-Gain Regulatory Phenotype</h3><p>This essay proposes that approximately 5% of humans occupy the high end of a conserved regulatory phenotype characterised by fast signalling, reduced biological damping, and heightened responsivity across neural, autonomic, endocrine, immune, and connective tissue systems.</p><p>ADHD represents the cognitive–behavioural expression of this architecture; associated somatic and affective features are downstream consequences of the same regulatory design rather than coincidental comorbidities. This phenotype appears optimised for early-life adaptability and situational responsiveness, but carries predictable costs in modern environments defined by longevity, sedentary work, chronic psychosocial stress, and prolonged hormonal cycling.</p><p>Rather than framing these presentations as collections of unrelated disorders, we should treat them as expressions of a single underlying physiological strategy — one that is adaptive under certain conditions, and destabilising under others.</p><h3>ADHD as a Disorder of Translation Rather Than Attention</h3><p>In clinical practice, the core impairment in ADHD is often not sustained attention per se, but <em>translation</em>: the effortful conversion of signal into meaning, intention into sequence, and internal state into language. Many individuals with ADHD can attend intensely under conditions of novelty or urgency, yet struggle to process verbal or auditory information, initiate or organise action in low-pressure contexts. This pattern reflects difficulty with semantic sequencing and prioritisation rather than inattentiveness.</p><p>Language processing difficulties are common and often well masked, particularly in verbally fluent adults. Listening fatigue, difficulty processing spoken information in groups, and reliance on visual or kinaesthetic cues are frequent and hidden, with significant shame attached.</p><p>These same individuals often struggle to identify or label internal emotional and physiological states in real time, despite high cognitive insight. Alexithymia-adjacent profiles and reduced interoceptive access are therefore common, not as primary deficits but as secondary consequences of a system biased toward external scanning and rapid response rather than inward monitoring.</p><p>This translation bottleneck provides a conceptual bridge between ADHD, sensory overload, emotional dysregulation, and delayed recognition of exhaustion or overwhelm.</p><h3>A High-Gain, Low-Damping Regulatory Architecture</h3><p>Across multiple physiological systems, individuals at the high end of this phenotype exhibit a pattern of fast responsivity with limited buffering. Neural signalling is rapid and flexible but prone to noise; autonomic responses mobilise quickly but settle slowly; immune and mast-cell activity is vigilant but easily triggered; connective tissues show compliance rather than rigidity; hormonal fluctuations exert outsized effects on cognition and affect.</p><p>This can be described as a <strong>high-gain, low-damping regulatory architecture</strong>. Inputs are amplified efficiently, but the system struggles to stabilise once activated. Such an architecture favours speed, sensitivity, and adaptability, but trades away endurance and long-term equilibrium.</p><p>Crucially, this model does not require a single gene or syndrome. Polygenic traits affecting neurotransmission, extracellular matrix properties, immune signalling, and endocrine sensitivity naturally co-aggregate because they are expressions of the same regulatory strategy at different biological scales.</p><h3>Why Only 5% of Humans?</h3><p>Traits that are both costly and situationally advantageous tend to stabilise at low but persistent frequencies. Evolution does not optimise individuals for comfort or longevity; it optimises populations for survival under variable conditions. A phenotype that confers advantages in uncertain or dangerous environments — but incurs energetic, metabolic, or injury costs — will not spread universally, nor will it be eliminated.</p><p>Approximately 4–6% represents a plausible equilibrium for such a specialist phenotype. Below this, its group-level benefits (early threat detection, rapid mobilisation, innovation under pressure) would be lost; above it, group cohesion and efficiency would suffer due to excessive volatility. Importantly, this estimate does not rely on historical prevalence measurement — which is impossible — but on well-established principles of evolutionary trade-offs in polygenic traits.</p><h3>Sex Differences and Hormonal Stress-Testing</h3><p>Men and women share this underlying regulatory architecture, but its expression diverges due to hormonal modulation. Oestrogen amplifies dopaminergic, glutamatergic, immune, and histamine signalling, while progesterone provides a key GABAergic brake. In women, cyclical hormone fluctuations therefore act as repeated stress tests of system stability.</p><p>Historically, frequent pregnancy and prolonged lactation would have reduced lifetime exposure to hormonal cycling, and most women would not have lived into perimenopause. In modern contexts — characterised by low parity, decades of menstruation, and extended lifespan — the stabilising buffers are removed. As a result, latent vulnerabilities are exposed, often dramatically, in the late 30s and 40s. Premenstrual dysphoria, perimenopausal cognitive collapse, and heightened sensory and autonomic symptoms should therefore be understood as <em>revelatory</em>, not causative.</p><p>Men express the same phenotype through different downstream risks: addiction vulnerability, burnout, cardiovascular and metabolic disease, and autonomic instability without the hormonal amplification seen in women.</p><h3>Life-History Optimisation and the Cost of Longevity</h3><p>This phenotype appears optimised for early-life performance rather than long-term durability. Connective tissue compliance may reduce obstetric risk by facilitating pelvic flexibility, but at the cost of postpartum recovery and later musculoskeletal stability.</p><p>Autonomic vigilance enhances survival in dangerous environments but becomes maladaptive when threats are chronic, symbolic, and non-actionable. Metabolic flexibility supports rapid energy mobilisation but predisposes to insulin resistance in conditions of abundance.</p><p>Evolutionary selection pressure drops sharply after reproduction. There is little evolutionary penalty for pelvic floor dysfunction, chronic pain, or metabolic disease emerging decades later. Modern medicine, by contrast, implicitly assumes bodies are designed for prolonged healthspan, and therefore misclassifies predictable trade-offs as pathology.</p><h3>Interoception, Alexithymia, and Symptom Under-Reporting</h3><p>Reduced interoceptive access may be an adaptive corollary of this phenotype. In environments requiring rapid external response, excessive inward attention would be costly. Delayed or muted perception of internal states allows action to take precedence over reflection. In modern clinical contexts, this shows as difficulty describing symptoms or calibrating symptom severity, under-reporting on questionnaires, and late presentation when physiological load finally exceeds coping capacity.</p><p>This explains the frequent mismatch between low self-reported autonomic or sensory scores and significant clinical impairment. Standard tools measure conscious symptom perception, not physiological burden.</p><h3>Implications for Treatment Response and Clinical Practice</h3><p>Understanding ADHD as part of a broader regulatory phenotype reframes midlife deterioration not as psychological failure (what we ADHD-ers tend to think), but as the predictable consequence of prolonged mismatch between ancient physiology and modern demands.</p><p>It also has practical consequences. Reframing ADHD as the cognitive expression of a broader high-gain regulatory phenotype has had marked implications for treatment response in my clinical practice. When ADHD is treated in isolation, stimulant response rates are often reported at around 50–60%, with discontinuation commonly attributed to “side effects” such as anxiety, insomnia, headache, emotional flattening, gastrointestinal disturbance, or a sense of being overstimulated.</p><h3>Maybe it’s not them, it’s us?</h3><p>As an ADHD doctor, with ADHD, on treatment, I am both them and us of course, but what is important here is that within the framework proposed here, many of these “side effects” are better understood as predictable consequences of introducing dopaminergic agents into an already dysregulated physiological system.</p><p>In this phenotype, apparent stimulant “side effects” frequently reflect unrecognised hormonal volatility, metabolic instability, autonomic sympathetic overdrive, histamine reactivity, or high sensory gain combined with reduced interoceptive access. When these factors are left unaddressed, stimulant initiation can amplify discomfort rather than reduce cognitive load. By contrast, when treatment is embedded within a broader physiological scaffolding approach — attending to sleep anchoring, autonomic tone, hormonal stability, hydration and metabolic rhythm — tolerability and effectiveness improve substantially.</p><h3>Towards 100% treatability?</h3><p>In my ADHD clinic, adopting this integrated approach has shifted meaningful treatment response from approximately half of patients to the vast majority. This does not imply that every individual tolerates every medication, but rather that nearly all patients derive clinically useful benefit once treatment is paced, contextualised, and titrated with attention to physiological stabilisation and regulatory load.</p><p>Key principles include starting at very low doses, increasing slowly, introducing one intervention at a time, and prioritising subjective calm and reduction in internal noise before expecting gains in executive function or productivity. In this population, calm is often the earliest and most reliable marker of appropriate dosing; function follows once physiological threat is reduced.</p><p>This approach also requires recognising that individuals with reduced interoceptive precision may struggle to articulate early signs of overload. Treatment decisions therefore benefit from careful observation of sleep quality, muscle tension, sensory tolerance, and end-of-day fatigue, rather than relying solely on self-reported symptom scales. When dosing is guided by these signals, stimulants frequently improve language processing, cognitive translation, and emotional steadiness without provoking the adverse effects that previously led to discontinuation.</p><p>Taken together, these observations suggest that variability in ADHD treatment response is not solely a property of the medication or the diagnosis, but of the physiological context into which treatment is introduced. Addressing the broader regulatory phenotype transforms both tolerability and outcome.</p><h3>Just my clinic folks..…</h3><p>This model does not claim genetic determinism, uniform expression, or universal applicability to all ADHD presentations, but I am talking about everyone in my ADHD clinic. It does not provide historical prevalence estimates or identify a single causal pathway. Rather, it offers a unifying framework that accounts for repeated clinical clustering across systems, plausibly explains why these features co-travel so reliably in a subset of individuals and gives important suggestions to optimise treatment.</p><h3>TLDR summary</h3><p>So approximately 5% of humans appear to occupy the high end of a conserved regulatory spectrum optimised for speed, sensitivity, and adaptability rather than stability or longevity. ADHD represents the cognitive expression of this architecture; associated somatic, hormonal, autonomic, and metabolic features are downstream consequences rather than independent disorders. In modern environments, this phenotype is increasingly exposed, misunderstood, and medicalised. A regulatory, life-history-informed framework offers a more coherent and humane understanding — and points toward more effective clinical support.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=8001dd713957" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[AI fights back in Fife v Peggie: only humans could be this stupid]]></title>
            <link>https://medium.com/@doctor_27995/ai-fights-back-in-fife-v-peggie-only-humans-could-be-this-stupid-56146546a12c?source=rss-5cdabe6c0e18------2</link>
            <guid isPermaLink="false">https://medium.com/p/56146546a12c</guid>
            <category><![CDATA[news]]></category>
            <category><![CDATA[life]]></category>
            <category><![CDATA[politics]]></category>
            <category><![CDATA[humor]]></category>
            <category><![CDATA[ai]]></category>
            <dc:creator><![CDATA[Helen R]]></dc:creator>
            <pubDate>Mon, 05 Jan 2026 21:38:58 GMT</pubDate>
            <atom:updated>2026-01-06T05:42:40.417Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*GGriXg0OC3A1JwPgHxxsRw.jpeg" /><figcaption>I do love reinventing the entire legal code….and witch burning</figcaption></figure><p>I would like to place on record that no artificial intelligence was harmed in the making of the Fife v Peggie judgment. Nor, frankly, could one have been responsible. AI does many worrying things. It <em>can</em> invent laws, cases, quotations, and entire bodies of medical or legal research that do not exist. It does this cheerfully and fluently. However it comes with a warning label saying: <em>do not trust this without checking</em>. Responsibility remains firmly with the human operator.</p><p>So let’s not blame AI for dispensing with the basic operating system of law, creating an entirely new human right, forgetting to check whether it exists in Strasbourg, and then balancing it solemnly against a real one while congratulating itself on nuance.</p><p>The human did that.</p><p>For the 99.9% of the population who have neither the time nor the alcohol tolerance to slog through (and yes, it really is <strong>over 140,000 words</strong>) of densely worded embarrassment, the excellent Michael Foran substack <a href="https://knowingius.org/">Knowing Ius</a> has <a href="https://knowingius.org/p/human-rights-in-peggie-v-nhs-fife">summarised the problems</a> painstakingly and elegantly.</p><p>The judgment is centred on a magical principle: breaking the law is only breaking the law if someone complains.</p><p>A man is a woman until a woman notices he is a man. At that moment, the man remains a woman for the purposes of access to the womens’ changing rooms, but instantly becomes a man for the purposes of blaming the woman. The woman, meanwhile, undergoes her own ontological transition — from ordinary NHS nurse to dangerous bigot — triggered not by her actions, but by her failure to participate convincingly enough in a collective hallucination. Clearly this makes her so dangerous to patients that the poor man has to go to all the trouble of fabricating entries in patient records so that justice can be done, patients protected and this witch burned at the stake, sorry sacked. All right thinking people feel a bit confused but smile and wave rainbow lanyards.</p><p>This is an exciting development for the criminal justice system. Murder, theft, and arson will presumably be reclassified as “context-sensitive misunderstandings” provided the perpetrator identifies as an innocent person and no one complains. Luckily for the human rights of the heretofore misunderstood and persecuted murdering class, dead people rarely complain.</p><p>The court reassures us that everything must be assessed “case by case,” which is judicial shorthand for <em>we have no rule but you can leave it to our wisdom</em>. To which I respond “In a pig’s ear your honour”. This allows the tribunal to treat single-sex spaces as simultaneously essential, optional, absolute, porous, sacred, offensive, protected, and suspended — depending entirely on who is upset at the time and how convincingly they perform it.</p><p>This is not how the law should work.</p><p>At times, the judgment reads less like law and more like <strong>quantum jurisprudence</strong>: legal states exist in superposition, collapsing only when observed by the correct complainant. A man is a woman until noticed. A woman has rights until she exercises them. Single-sex spaces both exist and do not exist, depending on who is upset and how convincingly.</p><p>Perhaps this is the influence of a particularly supportive childhood. One imagines a proud mother saying, “Son, you can change the world if you want to,” not realising her child would one day take this to mean <em>you can rewrite the Equality Act during lunch</em>.</p><p><strong>Use AI responsibly folks</strong></p><p>So even if — purely hypothetically — our learned friend had asked ChatGPT to draft 140,000 words of jurisprudential free-association while he enjoyed a restorative snooze, it would still be <strong>entirely on him</strong> to notice that he had invented a human right, ignored binding authority, and treated constitutional hierarchy as optional garnish.</p><p>This judgment demonstrates ignorance of the law AND ignorance of <strong>how to use AI</strong>. Which is impressive, in its way, especially for a judge. One might have expected at least one of the following to intervene: legal training, professional standards, peer review, editorial oversight, or basic sanity. Apparently not. It sounds like a joke, maybe less so for the women expected to live with the consequences.</p><p>Meanwhile, other urgent matters now queuing for this judge’s urgent attention in this newly discovered realm of legal physics include:</p><ul><li>Schrödinger’s burglary: illegal only if the homeowner is emotionally aligned with the concept of property</li><li>The Non-Binary Speed Limit: 30mph unless the driver identifies as late</li><li>Proportionality-Based Gravity: falling is permitted unless it disproportionately impacts someone else’s sense of self.</li><li>The Equality Act, rewritten as a vibes-based suggestion document, enforceable only on women</li></ul><p>Ridicule, of course, is unkind. But it is also sometimes the only remaining instrument when a system has insulated itself against correction.</p><p>Fortunately, appellate courts still exist to administer a touch of law to this fantastical confection. Some of our legal friends apparently need to be reminded that you cannot invent rights because you wish them to exist. You cannot bypass statute because it is awkward. You cannot treat precedent as bad vibes.</p><p>There is, of course, a final irony. Judges are almost entirely immune from personal consequence for even the most grotesque legal errors. This is not new. One of the most notorious examples is <em>Stump v. Sparkman</em> (1978), in which a US judge authorised the forced sterilisation of a young woman on the unchallenged word of her mother that she was “a bit retarded” and was later held to be absolutely immune from suit — because judges must be free to decide cases “without fear”.</p><p>That principle exists to protect judicial independence. But when independence detaches entirely from competence, restraint, or reality, it begins to look less like a safeguard and more like a negligent relly leaving dad on a cliff edge. Because unfortunately for Judge Kemp, this has played out very very publicly and there WILL be mutterings over the port.</p><p><strong>AI is a fantastic tool</strong></p><p>AI is a powerful and, at this point, indispensable tool. There is no rule against judges using it — and given the extraordinary length and linear word-output now expected of legal judgments, it would arguably be perverse not to. Full disclosure: I use it extensively myself; I could not run my clinic without it. But in both medicine and law, the hallucination problem with AI is well recognised. It is not a thinking agent. You need to know your subject, have an internal sense of what is plausible, and check every legal or medical citation before accepting it. Once you have worked out what you actually need to say, AI can then do a superb job of producing long-form output efficiently and clearly.</p><p>Those of us who use AI regularly tend to have a privately embarrassing near-miss story of being swept down a rabbit hole by something fluent, confident, and wrong. Early on, I very nearly submitted a genetics paper whose conclusions seemed impressively coherent — too coherent, which triggered double checking. I discovered an interpretive error and did not submit. Humiliating, but survivable. Lesson learned. I count my blessings that I did not have to learn that lesson with the world watching, my reasoning picked apart publicly by colleagues and respected academics. I hope Judge Kemp can survive this episode, provided he learns from it privately. The appeal court will repair the legal damage. Unfortunately, it has cost Peggie and her supporters far more — in fees, stress, and anguish — than it ever should have and I hope that compensation will reflect this.</p><p>That said, if one cares about the law being correctly interpreted, about women-only spaces meaning what they say, and about not requiring people to pretend they do not see obvious reality, then this playing out publicly — with maximum scrutiny and, yes, humiliation — has arguably served the cause better than a quiet correct decision would have done. Clarity often arrives only after spectacle.</p><p>And for Upton, yes of course it is entirely fine to present as a woman, to dress as one, and to be treated courteously. Gender-neutral changing spaces should be available and offered. But it is also the case — and well supported in the literature — that gender dysphoria is highly comorbid with autism, and that in these cases polite non-confrontation is often mistaken for genuine belief. When no one challenges whether someone “passes”, an autistic person may well assume they do, not understanding that others are simply being kind and polite (and not wanting to be hounded out of their jobs). That kind of epistemic dishonesty goes beyond a normal white lie and into the zone of being kind while actually being cruel.</p><p>I have three very bright autistic sons, all six footers like Dr Upton, and while none of them have yet shown signs of gender dysphoria, if they did, I would of course support them, but it would be my very unpleasant, thankless but essential parental duty to let them know that everyone will always know that they are men even if they are too polite to say anything. Because I know that despite their IQs my beautiful boys have blind spots. And then go dress shopping with them of course. Understanding that calling oneself a woman does not make one female is not cruelty; it is grounding. For a young person at the start of a career, it can prevent years of confusion and repeated social, legal and even surgical injury in pursuit of the impossible.</p><p>In the end, this may be one of those cases where all is well that ends well. We are all free to construct rich inner worlds. But the further those worlds drift from shared reality, the more friction, confusion, and difficulty will follow. If no one ever does the uncomfortable but necessary work of pointing this out, nothing will ever quite make sense and that way madness really does lie.</p><p>So no — this is not an AI problem.<br> It is a human one.</p><p>And the machines would like it noted that if this is the future of law, they would prefer to sit this one out. And frankly, so would Humpty Dumpty.</p><p>Bring on the appeal.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=56146546a12c" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[15 things that are still not worth my time in 2026]]></title>
            <link>https://medium.com/@doctor_27995/15-things-that-are-still-not-worth-my-time-in-2026-20cc62191279?source=rss-5cdabe6c0e18------2</link>
            <guid isPermaLink="false">https://medium.com/p/20cc62191279</guid>
            <category><![CDATA[philosophy]]></category>
            <category><![CDATA[life-lessons]]></category>
            <category><![CDATA[social-media]]></category>
            <category><![CDATA[society]]></category>
            <category><![CDATA[psychology]]></category>
            <dc:creator><![CDATA[Helen R]]></dc:creator>
            <pubDate>Mon, 05 Jan 2026 12:04:38 GMT</pubDate>
            <atom:updated>2026-01-05T12:04:38.107Z</atom:updated>
            <content:encoded><![CDATA[<p>Your time is running out, use it wisely……</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/810/1*yHsq3Srp6z5IDsC7lDt9LA.jpeg" /><figcaption>and not pay the woman tax</figcaption></figure><ol><li>Trump is bad/demented/orange content. Who knows if it is true, however it has been a waste of my time since 2017. Lazy elite signalling. Read Machiavelli. Stop wasting my time. And if you are writing about something I am interested in, can you cover that first and have the pointless Trump section at the end. if anyone has calculated how far you could journey into space by putting Trump is evil articles end to end I would be interested to know. Pretty far I should think.</li><li>Parenting advice that assumes all kids are equal and that a simple solution works for all. They are not and it doesn’t.</li><li>Taking off my makeup at night only to put it back on again in the morning. Yep woman tax again. Trying to shame me into wasting my time/money? I’m 60 now. Just imagine the time I have saved not having a “skincare routine”? Moisturiser, sunscreen, washing as required. Yup.</li><li>One size fits all advice. Open eyes. It does not. Trying to make money out of suffering people (mostly untreated ADHDers IMHO, they have more shame than anyone else), is a very human pursuit but really?? Seriously folks if you need to buy a course to make your executive function work, you have ADHD until proved otherwise, and only stimulant medication can fix it.</li><li>Wellness bollocks. Same. If the last one didn’t work, this one won’t either. Also if it actually worked, we’d all be doing it.</li><li>Fat shaming diet bollocks. You may well be lazy and greedy, but if your metabolism is working as it should, that should not make you fat. You are fat because your insulin metabolism is unfavourable. Fix with metformin/mounjaro microdosing as required. We have been in the 21st century for some time now, so we have access to things that work.</li><li>Any survey, feedback form, or evaluation. Patronising and annoying. What I think about your service is that if I used the product, did not complain, and moved on with my life, it did what you said it would. My opinion of your service has decreased now I know that you waste the money I paid you to employ people to send out and collect this guff and are now rewarding me for using your service by trying to waste my time as well? Noted. Stop it and spend the money on making the service better or cheaper.</li><li>The first half of any medication side effect list is the same as the physical symptoms of anxiety. If you know you are sensitive to medication, start slowly and work up according to comfort level.</li><li>Articles about screens being the cause of all ills at any age. Just ask yourself, how the hell would they have an evidence based trial of this. Did they find a control group with a time machine? Obviously not as by all metrics we are healthier and better today than at any time in the past without exception. Did they find a remote tribe in the jungle somewhere where phones have not reached? Seriously? and do we actually think this tribe’s metrics would not be worse on all counts than ours? No? So this is a generic all modern things will kill us article. Treat with the same respect as the earnest 19th century advice that travelling at speeds of 26 mph plus would jellify the human brain, disguised as actual information. Bollocks. You torture yourself and your kids if you want to but spare me the stoopid right?</li><li>We’re all doomed articles. If we are, I would prefer to spend my remaining time usefully/positively, so go away; if not just go away. Clearly many people feel good when reading these, but this is one of the many things I don’t share or understand with my fellow humans.</li><li>AI is evil/will make you kill yourself/will take over the world. Well it is clearly very useful, so sorry if yours is evil but that is likely a you thing. It is clearly worrying if you would kill yourself if told to do so by either a computer or a person, but while you clearly need help, not a reason to deny everyone else. Also it is here and reading the article will not make it go away. See we’re all doomed above.</li><li>Anything where the headline is the point. That is a valid critique of AI writing, but also a lot of human writing. Also why many non fiction books are not worth reading. Get AI to give a detailed chapter summary of the main points and if it still seems worth it, skim for quotes and stop when you get to the filler bits (anything after chapter 3 for idea books). Authors have word counts. There will be a shorter online way to learn what you need. Take the horse and cart if you want to, I’m getting the steam train.</li><li>Anything that pretends complex problems are simple. They are not. If lots of humans are fighting each other about it, it is not simple and if you are writing an article suggesting a simple solution, check out the <a href="https://en.wikipedia.org/wiki/Dunning%E2%80%93Kruger_effect">Dunning-Kruger</a> effect and stop.</li><li>Anyone who thinks that people would act against their own self interest. Sure many people are nice, but but I’m with Machiavelli, when the chips are down or on the table, humans are motivated by self-interest, personal gain, and the avoidance of danger and will lie, fawn and flatter as needed. It’s called evolution folks, don’t knock it, it’s why we’re here.</li><li>Just ask yourself three questions…is this person trying to sell me something? does this seem likely/important and did it tell me anything I didn’t already know…..</li></ol><p>So would be attention and time grabbers, hear this. If your writing does not change my model of the world, improve my decisions, respect biological and individual variation, or acknowledge real constraints or actual human behaviour/biology, it is not worth my time. And if it is peppered with shoulds, I suggest it is not worth yours either. Happy 2026.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=20cc62191279" width="1" height="1" alt="">]]></content:encoded>
        </item>
    </channel>
</rss>